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Criswell, Daniel C. Ph.D., May 2004 Molecular Biology
Characterization of Antibiotic Resistance Mutations m  Borrelia burgdorferi
This study has identified and characterized five Borrelia burgdorferi naturally 
occurring mutations conferring resistance to spectinomycin, kanamycin, 
gentamicin or streptomycin. These antibiotics target the small subunit o f the 
ribosome, which catalyzes protein synthesis. A naturally occurring coumermycin 
Ai-resistant mutant has also been characterized. Four other B. burgdorferi 
mutants have been created using site-directed mutagenesis conferring resistance 
to coumermycin Aj. Coumermycin Ai targets the B subunit of DNA gyrase, 
which catalyzes DNA supercoiling.
16S rRNA mutations, A l 185G and Cl 186U, homologous to Escherichia coli 
nucleotides 1191 and 1192, confer 1500-fold and 2500-fold resistance, 
respectively, to spectinomycin. These mutations appear in a population of B. 
burgdorferi wild-type parental strain B31-A at a high frequency o f 6 x 10'6. After 
100 generations in competition with wild-type B31 - A, 18% of the cells in a B31 - 
A+ C1186U culture was mutants and 8% of the cells in a B31-A+ A l 185G 
culture were mutants. A 16S rRNA A1402G mutation confers over 100-fold 
resistance to kanamycin and gentamicin. These mutants appear at a frequency of 
1 x 10'8 in a population of B31 and are unable to compete with B31-A after 100 
generations. Two streptomycin-resistant mutations were identified in the S12 
ribosomal protein. A K88R mutation conferred seven-fold resistance and a K88E 
mutation conferred 10-fold resistance to streptomycin. Both exhibited only the 
streptomycin-resistant, SmR, phenotype. The frequency of the streptomycin- 
resistant mutants was 3 x 10"9 and the K88E mutant was unable to compete with 
B31-A at 100 generations.
Coumermycin Ai-resistant mutants were constructed with amino acid 
substitutions in gyrase B of T162F, T162L, T162M and T162S. These mutants 
were from 5 to 6000-fold resistant to coumermycin A\. The naturally occurring 
T162I mutant was 420-fold resistant to coumermycin Ai.
Director: D. Scott Samuels
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Borrelia burgdorferi is a tick-bome pathogen that causes Lyme disease in 
humans (1). Although the entire genome of B. burgdorferi has been sequenced 
(2) a limited number of molecular tools are available to use in manipulating this 
genome (3). An important factor in developing these tools is choosing selectable 
markers that allow molecular biologists to identify clones of interest. A high 
mutation rate conferring resistance to an antibiotic used for selecting clones, or a 
high frequency in the population of organisms resistant to the antibiotic of choice, 
interferes with selection. In addition to the utility for molecular manipulation, 
many microorganisms have become resistant to a host of antibiotics that are, or 
have been, medically significant (4, 5, 6). Studies on the mechanisms of how 
resistance is acquired and maintained may further the understanding of how to 
avoid or eradicate resistant organisms that were once susceptible to a class of 
antibiotics.
The genome of B. burgdorferi is unusual for bacteria. It has a number of 
linear plasmids with covalently-closed hairpin loops at the telomeres and several 
circular plasmids in addition to a single linear 910 kb chromosome (2). Within 
the linear chromosome are two copies of the 23 S and 5S rRNA genes and a single 
copy of the 16S rRNA gene (7, 8). The secondary structure and sequence of the 
B. burgdorferi 16S rRNA is nearly identical to that of many bacteria including
1
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Escherichia coli and Thermus thermophilus and to eukaryotic chloroplast 16S 
rRNA found in Chlamydomonas and Nicotiana (9). These sequence and 
structural homologs are particularly helpful in providing clues of where possible 
mutations that confer resistance to a particular antibiotic would be located in the 
B. burgdorferi genome.
Many antibiotics, such as spectinomycin and the aminoglycosides, target 
bacterial ribosomes preventing translocation of tRNAs during translation 
(spectinomycin) or causing errors in accurately selecting cognate tRNAs 
(aminoglycosides) (10,11,12, 13). Other antibiotics, such as the coumarins, 
prevent DNA gyrase from introducing negative supercoiling, which is necessary 
for normal replication, recombination, and transcription. Some mutations can 
prevent binding by these antibiotics or compensate for antibiotic binding, while 
maintaining or restoring near normal levels of ribosomal or DNA gyrase function. 
A short review of ribosomal function and a literature review of mutations that 
confer resistance to these antibiotics will assist in understanding the results of this 
study, which identified the mechanisms of antibiotic-resistance in Borrelia 
burgdorferi.
1.2 Ribosomes
In E. coli, a typical prokaryote and model organism for ribosomal 
function, the 16S rRNA combines with 21 proteins to form the 30S ribosomal 
subunit. The 23 S and 5S rRNAs combine with 31 proteins to form the 5 OS 
ribosomal subunit (10). These subunits assemble to form a 70S ribosome during
2
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protein synthesis. Initiation of protein synthesis occurs when translation initiation 
sequences on mRNA bind by complementary sequences along the 16S rRNA of 
the 30S subunit. An initiation complex forms when initiation factors, f-Met- 
tRNAfMet (the initiator tRNA), the 3 OS subunit, mRNA and the 5 OS subunit 
assemble (10). The peptidyl sites (P-site) located on both the 30S and 50S 
subunits are occupied by f-Met-tRNAfMet upon assembly of the initiation complex 
(10). Elongation of the polypeptide chain begins as a cognate tRNA recognizes 
the correct codon on mRNA, occupies the A-site (which is also comprised of 
portions of both ribosomal subunits), and forms a peptide bond with the 
polypeptide chain attached to tRNA in the P-site (peptidyl tRNA) of the 70S 
ribosome (10). The now uncharged (no amino acid) peptidyl tRNA is released as 
the A-site tRNA (aminoacyl tRNA) possesses the polypeptide chain becoming the 
peptidyl tRNA. Translocation occurs when the aminoacyl tRNA with the 
polypeptide chain in the A-site moves to the P-site with the assistance of 
elongation factor G and the expenditure of energy provided by hydrolyzed GTP
(10). These procedures are repeated until the polypeptide is formed and 
translation terminates when the ribosome reaches a stop codon on mRNA. A 
review of this process is illustrated in Figure 1.








Figure 1. Basic ribosome structure and the translation cycle. (A) 16S rRNA is 
part of the 30S subunit. (B) An initiation complex forms when initiation factors 
(IF2), f-Met-tRNAfMet (the initiator tRNA), the 30S subunit, mRNA and the 50S 
subunit assemble. (C) The E (exit) site, P (peptidyl) site, and A (aminoacyl) site 
on the 70S ribosome with f-Met-tRNAfMet. (D) Selection of cognate tRNA. A 
charged aminoacyl tRNA binds at the A-site. (E) Translocation of the peptidyl 
tRNA to the E-site and the aminoacyl tRNA to the P-site after a peptide bond was 
formed between the peptidyl tRNA amino acid and the aminoacyl tRNA amino 
acid.
4
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1.3 Antibiotic Resistance
There are only a few reports of antibiotic resistance in B. burgdorferi and 
only one example of resistance to an antibiotic that targets the ribosome (14,15). 
B. burgdorferi strain N40 was shown to be >3000 times more resistant to the 
macrolide erythromycin than strain B31-A (14). In vitro experiments have shown 
B. burgdorferi to be susceptible to this antibiotic (16,17), which contrasts with 
clinical trials that were ineffective in treating Lyme disease in humans and 
animals (18, 19). Differences in the physiology of B. burgdorferi when grown in 
culture instead o f a host have been proposed as a possible mechanism for this 
discrepancy (19). Although the mechanism of resistance has not been identified in 
strain N40, erythromycin-resistant clones selected on solid medium showed 
changes in colony morphology and lack of growth in liquid medium indicating 
resistance may be due to changes in metabolism (14). Metabolic changes 
associated with antibiotic resistance and affecting normal functions such as 
colony morphology and size, cell aggregation, and cell adhesion have been 
identified previously in Pseudomonas aeruginosa (20). Sequencing the 23 S 
rRNA gene revealed that the mechanism of erythromycin resistance conferring 
resistance in B. burgdorferi strain N40 is not a mutation in the 23 S rRNA, a 
common site in other bacteria such as Streptococcus pneumoniae (21). An 
A2059G mutation in the 23S rRNA of S. pneumoniae conferred resistance to 
erythromycin, and as the number of alleles with this mutation increased, the level 
of resistance also increased.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1.4 Spectinomycin Resistance
Spectinomycin is an aminocyclitol antibiotic produced by several species 
of Streptomyces, including S. flavopersicus and S. glebosus (22), which targets the 
30S ribosomal subunit of many gram-negative bacteria. In E. coli and T. 
thermophilus, spectinomycin blocks elongation of the polypeptide during protein 
synthesis by preventing the translocation of the peptidyl tRNA from the A-site to 
the P-site (11,12,13). The antibiotic inhibits the activity of elongation factor G, 
which binds GTP and promotes translocation of the ribosome along mRNA (11, 
13). Associated with the translocation process is helix 34 (H34, Figure 2) o f 16S 
rRNA that comprises a portion of the A-site. Rotation of H34 and other elements 
of the 16S rRNA head enable the movement of mRNA along the ribosome and 
subsequently the translocation of tRNA from the A-site to the P-site. This 
movement is inhibited by the rigid spectinomycin molecule when it forms 
hydrogen bonds with several bases including G1064 and Cl 192 homologous to B. 
burgdorferi 1058 and 1186, respectively, in the minor groove of H34 (11, 12, 23). 
Translocation of tRNA not only involves movement of H34 but possibly H35 and 
H38 as well (11). Spectinomycin binding stabilizes H34 and could sterically 
hinder its movement, or prevent conformational changes necessary for 
translocation (11).
E. coli has been shown to be resistant to spectinomycin when nucleotide 
1064 or the base-paired partner at 1192 in H34 of the 16S rRNA are mutated (12). 
T. thermophilus is also spectinomycin resistant when the base-pair G1064 and 
Cl 192 are mutated (11). (E. coli numbering will be used throughout the text
6
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unless otherwise noted.) Currently, most mutations at these sites are hypothesized 
to reduce the overall stability of H34 restoring the movement necessary for the 
translocation of tRNA even while spectinomycin is bound (11). Thermodynamic 
studies of all mutations at these sites have been shown to reduce the stability of 
H34 with the exception of the Cl 192G mutant (12,24,25). A C l 192G mutation 
combined with the compensatory mutation, G1064C, actually increases the 
stability o f H34 (25) and are accompanied by a five-fold decrease in growth rates 
when compared to wild-type (12). This double mutant interferes with the 
assembly of the 70S ribosome, reducing ribosomal activity and causing decreased 
growth rates in E. coli (11,12). This might be particularly important for B. 
burgdorferi since it has only one copy of the 16S rRNA gene (rrs) compared to 
the seven copies in E. coli. The Cl 192G and G1064C mutations may prevent the 
assembly of functional ribosomes, and consequently inhibit growth of B. 
burgdorferi since it lacks another 16S rRNA. Analysis of translational efficiency, 
using chloramphenicol acetyl transferase (CAT) as a reporter, with the mutations 
G1064A, C, or U and Cl 192U showed little effect on ribosomal activity in E. coli 
in the presence of spectinomycin indicating these mutations have little effect on 
growth rates (12). By comparison, CAT activity for the Cl 192G-G1064C double 
mutant was 20% of normal, which explains the observed decrease in growth rates 
(12). In addition to the changes observed in ribosomal activity and growth rates, 
differences in levels of spectinomycin resistance by different base substitutions 
have also been observed. A Cl 192A mutation gives low levels of resistance while
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
substitutions at this site to U or G give high levels of resistance to spectinomycin 
(24).
Mutations at sites 1191 and 1193 in the chloroplast 16S rRNA of C. 
reinhardtii and A. tabacum confer resistance to spectinomycin for these 
eukaryotic organisms as well (26,27). As with E. coli mutants, different levels of 
resistance correspond to mutations at different sites. A G1193 A mutation confers 
low-level resistance to spectinomycin while Al 191G and A l 191C mutants result 
in high-levels of resistance in C. reinhardtii (26).
Mutations that result in amino acid substitutions in the S5 protein of the 
3 OS ribosomal subunit confer resistance to spectinomycin in E. coli and T. 
thermophilus. Two different strains of E. coli have been shown to be resistant to 
spectinomycin when serine of the VSK tripeptide (residues 20-22) is mutated to 
proline creating a S21P substitution (27,28,29). Although S5 does not directly 
interact with the antibiotic (11, 28), resistance is probably due to destabilization of 
the tertiary structure formed by interactions of the 16S rRNA with the protein (11, 
30). Structural changes in the S5 protein may cause a shift in the structure of the 
upper stem of helix 34 making it inaccessible to spectinomycin (11).
Spectinomycin is not used as an antibiotic to treat Lyme disease but is 
currently used to treat infections by strains of Neisseria gonorrhoeae. Many 
antibiotic-resistant strains of A. gonorrhoeae have emerged in the past few years, 
but spectinomycin continues to be effective in treating gonococcal infections 
world-wide (31, 32, 33). However, clinical isolates of A. gonorrhoeae that are
8
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spectinomycin-resistant have been identified. As expected, these resistant strains 
had G1064C and Cl 192U mutations in the 16S rRNA (34).
1.5 Kanamycin and Gentamicin Resistance
Kanamycin and gentamicin are aminoglycosides produced by 
Micromonospora and Sirepiomyces species. They are both 2-deoxystreptamine 
antibiotics belonging to the 4, 6-disubstituted class of aminoglycosides (35). The 
two antibiotics are structurally similar with the main difference of two additional 
amine groups on gentamicin (35). Kanamycin is of particular interest since many 
organisms have become resistant to this antibiotic by mutations in their 16S rRNA 
genes or by possessing genes whose products catalyze acetylation, 
phosphorylation or methylation of aminoglycosides, or by modifications to the 
16S rRNA gene (36, 37, 38). Both antibiotics cause miscoding of mRNA upon 
binding to the 16S rRNA (35, 36). These antibiotics bind to the major groove of 
helix 44 (Figure 2) in a pocket formed by the non-canonical base-pairing of 
A1408 and A1493 and the bulged nucleotide A1492 (39). This region 
encompasses a portion of the A-site and includes the universally conserved 
A 1492 and A 1493 sites that are essential for E. coli ribosomal function and 
viability (39,40). Gentamicin and kanamycin form several hydrogen bonds along 
the major groove of H44 including G1494, U1495, G1405 and U1406 (39, 41). 
Hydrogen bonds are also formed with A1408 (G1408 in eukaryotic organelles) 
and stacks against G1491 causing the phosphate backbone of A1492 and A1493 
to flip out and lock into this position (11, 36). In this locked position, the affinity
9
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for cognate and noncognate tRNAs at the A-site is increased causing errors in 
reading mRNA transcripts (11). In the absence of antibiotic, this region would be 
free to rotate during the decoding step, reducing or eliminating translational errors 
(11).
A mutation at site U1406 or A1408 confers resistance to gentamicin and 
kanamycin in E. coli (36). A U1406A mutation in E. coli confers low level 
resistance to kanamycin and gentamicin while increasing the culture doubling 
time from 60 to 90 minutes (36). The slower growth rate, which is typical of 
hyperaccuracy, would indicate there is some interference of ribosomal function. 
Hyperaccuracy occurs when the ribosome becomes too selective for tRNAs, 
slowing down elongation of polypeptides and subsequently growth. An A1408G 
mutation in E. coli causes no change in the doubling time and apparently does not 
interfere with ribosomal function, but does confer high levels of resistance to 
these antibiotics (36). Footprinting studies have demonstrated that resistance in 
these two mutants results from decreased binding affinity of kanamycin and 
gentamicin to H44 (36,42). This inability to bind is caused by the distortion 
created in the binding pocket as a result o f the base substitutions at either 1406 or 
1408(42).
Many microorganisms can become kanamycin and gentamicin-resistant. 
For example, an A1408G mutation and several C1409 mutations confer high 
levels of resistance (>500 fold) to kanamycin in several species of Mycobacterium 
(43, 44). An A1408G mutation in C. reinhardtii resulted in high levels of
10
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resistance to kanamycin, while a C1409U mutation confers lower levels of 
resistance (26).
1.6 Streptomycin Resistance
The aminoglycoside streptomycin, like spectinomycin, is an antibiotic 
produced by Streptomyces species. This antibiotic disrupts translational accuracy 
by increasing the affinity for noncognate aminoacyl tRNA molecules and 
interfering with the ability to accurately proofread during translation (45,46).
This error-prone activity is induced when streptomycin forms hydrogen bonds at 
several sites along the 16S rRNA phosphate backbone and the ribosomal S12 
protein (11, 47). In E. coli and T. thermophilus, studies involving mutagenesis, 
cross-linking, and crystallography have identified several bases in the 16S rRNA 
and a residue in S12 as binding sites for streptomycin (11,48,49, 50). These sites 
include 16S rRNA C526 and G527 in the 530 loop located within H18, A913 and 
A914 of the 900 stem loop in H27, C l490 and G1491 of H44, and U14 in the 16S 
5' end (Figure 2) (11). The single contact in S12 is at residue K45. Single 
mutations in the 16S rRNA or the S12 gene, rpsL, in E. coli have been shown to 
cause resistance to streptomycin (47,48,49, 51). These include, but are not 
limited to, the 16S rRNA sites 523, 885-890, and 910-912, and the S12 residue 
K45. Mutations at homologous sites in the 16S rRNA and the S12 protein also 
confer resistance to streptomycin in many other organisms (52, 53, 54, 55). A 
K88N mutation in the S12 protein of Mycobacterium tuberculosis (52) and a 
C912U mutation in the chloroplast 16S rRNA of the eukaryote Euglena gracilis
11
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(53) have been shown to confer streptomycin resistance in these organisms. 
Wild-type 18S rRNA in yeast has a U at site 912 that confers natural resistance to 
streptomycin. When the reverse mutation is made, U912C in yeast 18S rRNA, 
these organisms also become susceptible to the antibiotic (56).
Mutations in the 16S rRNA and S12 protein can produce several different 
E. coli phenotypes with respect to streptomycin resistance. These phenotypes 
result from mutations of sites in the helix 27 “accuracy switch” (49). Helix 27 has 
been proposed to have two possible base-pairing patterns during translation.
Bases 910-912 are paired with bases 885-887 in what is termed the ribosomal 
ambiguity or ram state, which has a high affinity for tRNA (49, 57, 58).
Transient switching of the base pairing of 910-912 to bases 888-890 moves the 
16S rRNA into the restrictive or proofreading state that lowers its affinity for 
tRNA (49). In the restrictive state, the S-tum motif of H27 that was present in the 
ram state is disrupted, changing the packing between H27 and H44. This change 
in conformation by H27, which contacts several other helices, probably causes 
conformational adjustments by these adjacent helices as well (11). Chemical 
protection experiments show that residues of these helices are more chemically 
reactive in the restrictive state, which is consistent with the proposed 
conformational changes (11). The contacts that S12 makes in this region probably 
facilitate the switch mechanism in H27 (49). Streptomycin binding is 
hypothesized to stabilize the area and prevent switching to the restrictive state, 
increasing the affinity for noncognate tRNA and, consequently, errors in 
translation (11). With the addition of streptomycin, the 16S rRNA is locked into
12
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the error-prone ram state and unable to switch to the hyperaccurate restrictive 
state to proofread and eject non-cognate tRNAs (11). The presence of the S12 
protein is also believed to stabilize this region. An S12 mutation may destabilize 
the region compensating for the increased stability conferred by streptomycin
(11). This possibility would allow the ribosome to switch to the restrictive state, 
edit the translational errors and function fairly normally even while bound to 
streptomycin (11). This streptomycin-resistant E. coli phenotype is designated 
SmR (59). A mutation at one of the previously mentioned sites in 16S rRNA, 
destabilizing the region, also produces a SmR phenotype (11). Mutations that 
produce the SmR phenotype do not provide cross-resistance to other 
aminoglycosides such as kanamycin and gentamicin (60).
Another streptomycin phenotype results from mutations in the small 
subunit proteins or multiple mutations to 16S rRNA. This phenotype is called 
streptomycin-dependent and is designated SmD (61). Mutations in the S4, S5 and 
S12 proteins or multiple mutations in 16S rRNA force the ribosome to remain 
predominately in a restrictive state. Streptomycin binding stabilizes the ram state 
restoring ribosomal function by permitting the ribosome to switch between the 
error-prone ram state and the hyperaccurate restrictive state (11). The SmD 
phenotype is cross-resistant to kanamycin and gentamicin, which provides another 
method for verifying the SmD phenotype (60).
Specific mutations to the S12 protein have been shown to produce either 
the SmR or SmD phenotypes in several organisms, including is. coli, T. 
thermophilus and Salmonella typhimurium (62, 63, 64). In T. thermophilus,
13
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single mutations in the rpsL gene resulting in amino acid substitutions P41S, 
K42R, K88E or K88R in the S12 protein resulted in a SmR phenotype (62). Each 
of these mutations gave high levels of resistance to streptomycin with the P41S 
mutant being about half as resistant as the others. Culture doubling times for each 
of the mutants were increased over the wild-type. K88E had the longest increase 
in doubling time at 90 minutes, while K88R had the smallest increase at 56 
minutes compared to the doubling time for wild-type T. thermophilus o f 50 
minutes (62). The frequency of these mutants was reported to be 10'7(62), which 
is about three orders of magnitude more frequent than the homologous mutations 
mE. coli (2 x 10‘10) (63,65).
14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
, A A UCU
' 'U q G G A .
A A C U G U G Q A  U A U O U  U G G A  
C I I I I I I *  M i l  -  I ’ l l  , ,
U c G A C A C C A  A U A C G  A UC U GW J A U A U A G ©  *
CC C A U ° U tillV ° G C  6I I
C G  <3
G I I  I I I  I 
q U G C U C G
I I I *  I I I I  t I I 
A G G A G U  a a u a g a c
H ‘
qg g  o u g 0 u
C G  • UA U A A U U A U UI I I ■ I I I - - u  
G A UU GA U A u A ® g  / ^ A yV//
A U AU G U C
u c - gM
g c a c a c u u ® . '* / ! a  
A.  I I I I I I I CV 




GGG G C U C GI i lk -III
CLTC. _ U G AG A  AaA<3
A — U
G O A  
C A A
/ /  (A A U U G A C G G G G C C C 6 CACAA<3
c . .  I I  I I • •  I I I I Mil I I
u  AC. U G U  U C C G G
G « U c
G \
u A a .  Hjv  a ag - c  Gi r \  _
A GA U U~ A U U C  ?GC\ N AAU
I I  • » I I I I \ \
q C U G G  U A A G U ^ j C g
A g a AG »CUy \ ^ G  G
gVgu%ga
Ac\̂3 \ n
a g c c u g a  c g g a g c v \ g u u a g c c g u a c u gI 11 I I • I 11 
G U C G G C G U G A AI I I
g c g g g u  g c c u c  
a a c  u u
A O GUu
U - A A
«//V CAfl’c 
V/°
g A C G 
\  A°iGUCA A G G UC
AG 6 g  GA
A • /  ,°u A
GUC  A CG G G A U G U  AG 
I M O |  • I I I I  I 
CG G  U G A C U U A C A U A
A -  U
C •  U
Borrelia burgdorferi
(M88329)
1. Bacteria 2. Spirochaet aleS. Spirochaetaceae 
4. Borrelia 5. Borrelia burgdorferi group 
November 1999
AA A G C U C U C G 
U H U - 1  
UU c C G A A G G
„ G * " A
V 500/
A C U A U U A G
♦  I I I • I I ?  
C G A U G A U A
Citation and related information available at http://ww w .m a.icm b.utexas.edu
Figure 2. Borrelia burgdorferi 16S rRNA secondary structure map. Each box is 
labeled with the appropriate helix. Modified from www.ma.icmb.utexas.edu/ (9)
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1.7 Coumermycin Ai Resistance
Coumermycin Ai is an antibiotic in the coumarin family produced by 
Streptomyces species (66). This antibiotic targets DNA gyrase (67), a type II 
topoisomerase that introduces negative supercoiling in DNA, which relieves 
torsional stress during replication or transcription (68). Gyrase is an A2B2 tetramer 
encoded by two genes, gyrA and gyrB. Gyrase A catalyzes the breakage and 
reunion of double-stranded DNA and gyrase B contains the ATP binding site 
involved in ATP hydrolysis (68). Coumermycin Ai binds to gyrase B inhibiting 
ATP hydrolysis and growth (68).
The coumarin antibiotic novobiocin interacts with the universally 
conserved residue T165 (T162 in B. burgdorferi) of GyrB in E. coli (69). A 
mutation at E. coli T165, and homologous residues in other bacteria, has been 
postulated to confer resistance to coumarin antibiotics including coumermycin Ai 
(69, 70, 71). Mutations at other residues have also been shown to confer 
resistance to coumermycin Ai in several organisms. Several mutations in 
Staphylococcus aureus have been shown to confer high resistance to 
coumermycin Ai, including a T165N mutation (70). Mutations in Bartonella 
bacilliformis at residues G124, R184 and T214 (homologous to G77, R136, and 
T165 in E. coli) are up to five-fold resistant to coumermycin Ai (71). These 
residues correspond to residues G74, R133, and T162 in B. burgdorferi. In E. 
coli, R136 substitutions, homologous to B. burgdorferi R133, conferred a 10-fold 
increase in resistance to coumermycin Ai (72). Three different amino acid 
substitutions, R136C, R136H, and R136S, conferred high levels of resistance to
16
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coumermycin Ai; however, gyrase activity was impaired (72). Mutations in B. 
burgdorferi gyrB, which resulted in substitutions at residue R133 to G or I also 
provide resistance to coumermycin Ai (73). Furthermore, our laboratory has 
found that any amino acid substitution at R133 will confer resistance to 
coumermycin At (B. Eggers, C. Eggers and D.S. Samuels, unpublished data.) 
The naturally occurring mutations G74S or T162I also have been identified as 
conferring resistance to coumermycin Ai in B. burgdorferi (D.S. Samuels, 
unpublished data).
1.8 Objectives
The goal of this project was to identify and characterize Borrelia 
burgdorferi mutants that are resistant to the antibiotics coumermycin Ai, 
spectinomycin, kanamycin, streptomycin, and gentamicin. Mutants resistant to 
spectinomycin, streptomycin, kanamycin and gentamicin have been found 
resulting from mutations in the genes encoding the 3 OS ribosomal subunit, 
including the 16S ribosomal RNA and the S12 protein. Mutants resistant to 
coumermycin Ai have been constructed by site-directed mutagenesis in the gene 
encoding the B subunit of DNA gyrase. This study focused on genetically 
identifying the site o f resistance to these antibiotics and the fitness o f each 
antibiotic-resistant mutant.
1.9 Specific Aims
1. Spectinomycin resistant mutants were isolated and characterized. We have 
observed naturally occurring mutants o f B. burgdorferi that are resistant to the
17
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antibiotic spectinomycin. The frequency of mutation was determined by plating 
108 and 107 cells of B. burgdorferi in different concentrations of spectinomycin 
and counting the number of resistant colonies that appeared on the plate. The 
location of the mutation conferring resistance was determined by sequencing the 
single gene for the 16S rRNA. Susceptibility assays, measuring the concentration 
that inhibits growth of 50% of the cells (IC50), were used to gauge the level of 
resistance to spectinomycin by the resistant mutants. A mutant 16S rRNA gene 
that was spectinomycin-resistant was cloned into the vector pBSV2RII and 
transformed into wild-type B31-F to determine if  resistance in the resulting 
merodiploid was recessive or dominant. The pBSV2RII plasmid alone was also 
transformed into wild-type B31-A as a control.
2. Aminoglycoside-resistant mutants were isolated and characterized.
We have found mutants resistant to the aminoglycosides streptomycin, kanamycin 
and gentamicin. As with the spectinomycin-resistant mutants, plating 108 and 107 
cells in 50 pg/ml of the respective antibiotic and counting the number of colonies 
that appeared on the plates was done to determine the frequency of these 
mutations. The location of these mutations was determined by sequencing the 
gene for the 16S rRNA. Streptomycin-resistant mutations were also found in the 
rpsL gene that codes for the S12 protein of the 30S ribosomal subunit. 
Susceptibility assays (IC5 0) were performed to determine the levels of resistance 
to each of the antibiotics. Each antibiotic-resistant mutant was tested for cross­
resistance to the other aminoglycosides and spectinomycin to assist in identifying 
the cause of resistance.
18
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3. The genetic fitness of the spectinomycin- and aminoglycoside-resistant 
mutants was assayed. A competition assay was performed to test each of the 
mutants against wild-type B. burgdorferi to see if there is a growth advantage or 
disadvantage in possessing a particular mutation to one of the antibiotics. We 
hypothesized that the high frequency of the spectinomycin-resistant mutants is a 
result of no cost or an attenuated cost to the organism that does not significantly 
affect growth.
4. Coumermycin Ai-resistant mutants were constructed and characterized.
Random site-directed mutagenesis was used to introduce mutations into the gene 
for the B subunit of DNA gyrase. These mutations change amino acid residue 
162 from threonine to any of the other nineteen amino acids. Mutants gyrB genes 
were sequenced to identify the amino acid conferring resistance to coumermycin 
A\. Each of the coumermycin Ai-resistant clones underwent a susceptibility assay 
to determine its level of resistance. A growth assay was done to determine if  there 
is any significant difference in doubling times for the mutants when compared to 
the wild-type.
19
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Chapter 2 
Materials and Methods
2.1 Isolation of Antibiotic-Resistant Mutants
Spectinomycin Resistance. Borrelia burgdorferi strain B31-A was grown 
in 10 ml of liquid Barbour-Stoenner-Kelly (BSK-H) medium (Sigma) at 34°C to a 
concentration of 108 cells/ml. The cell density was determined by a 
spectrophotometer at an optical density (OD) of 600nm. One ml of liquid culture 
was centrifuged at 10,000 rpm for 10 minutes, resuspended in one ml of dPBS++ 
(8.0g NaCl, 0.2g KC1,1.15g Na2HP04,0.2g KH2 P 0 4, O.lg CaCl2, and 0.213g 
MgCl2/L) and the optical density at 600nm (OD600) was determined. The OD60o 
was multiplied by 1.4 x 109 to calculate the number of cells/ml (74). To determine 
the frequency of spectinomycin resistance cells in the B. burgdorferi population
o
and to estimate the resistance levels of these strains, one ml (10 cells) of this 
culture was plated in semi-solid BSK medium (75) with spectinomycin (Sigma) at 
concentrations of 1.5 pg/ml, 6.0 pg/ml, and 30 pg/ml. 100 pi (107 cells) were 
plated at the same spectinomycin concentrations. The plates were incubated at 
34°C for 11 days before colonies appeared. This procedure was repeated 
independently seven times. Seven spectinomycin-resistant colonies were isolated 
from the plates and grown in 10 ml o f BSK medium containing 1.5 pg/ml o f  
spectinomycin, until 108 cells were present in the growth medium. DNA was 
extracted from each of the clones grown in liquid BSK as previously described 
(74). Spirochetes from the 10 ml cultures were centrifuged at 10,000 rpm for 10
20
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minutes. The pellet was washed with one ml dPBS++ and then resuspended in 
200 pi of 50 mM TES (Tris-HCl pH 8, 50 mM EDTA, 15% sucrose). The cells 
were lysed by adding 23 pi of 10% sodium dodecylsufate (SDS) and incubated at 
37° C for 30 minutes following the addition of 3 pi of proteinase K. The lysate 
was extracted using an equal volume of phenol-chloroform-isoamyl alcohol 
(25:24:1). DNA was precipitated by adding 8 pi of 5M NaCl and 400 pi of 100% 
ethanol and incubated at -20° C. The precipitated DNA was recovered by 
centrifugation for 25 minutes at 13,000 rpm, washed with 70% ethanol, and 
suspended in 50 pi of 10 mM Tris-HCl (pH 8.0).
The 3' end of the 16S rRNA gene was amplified using 16S 40F and 16S 
659R (Table 1) in a polymerase chain reaction (PCR) since this is where known 
spectinomycin-resistant mutations are located in other organisms. The reaction 
produced a 620 base pair DNA segment. DNA for the sequencing template was 
purified using a Qiaquick® PCR purification kit and 15 pi at a concentration of 10 
ng/pl were sent with the two primers to the Murdock Molecular Biology Facility 
for sequencing. The DNA sequencing template was also amplified using the 
same technique to sequence the rpsE gene, which codes for the S5 protein. The 
primers used in this PCR reaction were rpsG U322F and rpsE 441R (Table 1).
Aminoglycoside Resistance. The same techniques were used to isolate 
and identify streptomycin-, kanamycin-, and gentamicin-resistant mutants, as 
described above for the spectinomycin-resistant mutants. BSK plates were made 
with 40 pg/ml kanamycin, 35 pg/ml streptomycin, or 30 pg/ml gentamicin. Two
o
sets of plates, one with 10 cells and one with 10 cells, were made using the
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antibiotic concentrations above. This procedure was repeated five times. When 
antibiotic-resistant colonies were not consistently isolated on streptomycin and 
gentamicin plates at concentrations of 108 cells, 109 cells were plated for all three 
antibiotics.
Three kanamycin-resistant strains, designated KAN1, KAN3 and KAN4, 
were picked and grown as described for spectinomycin-resistant colonies, except 
with 40 pg/ml of kanamycin added to each culture tube. DNA was extracted using 
standard protocols and the 16S rRNA gene was sequenced for mutations 
associated with resistance to kanamycin. The primers 16S 40F and 16S 659R 
(Table 1) were used for amplifying the 16S rRNA gene by PCR. The same 
procedures used for the spectinomycin-resistant mutants were followed for 
purifying the PCR product and sequencing DNA.
One gentamicin-resistant strain was selected and grown in liquid medium 
with 25 pg/ml gentamicin. From this 10 ml culture, DNA was extracted and 
purified for sequencing the 16S rRNA along with the spectinomycin- and 
kanamycin-resistant isolates using the same primers. The gentamicin-resistant 
strain was designated GEN2.
Four strains from the 35 pg/ml streptomycin plates were isolated and 
grown in BSK medium with streptomycin following the previously described 
procedures. DNA was extracted following standard protocols from the cultures 
designated SmRl, SmR2, SmR3 and SmR4. Due to the possibility that a 
mutation in several sites of the 16S rRNA gene might confer resistance to
22
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streptomycin, the entire gene was sequenced using the primers indicated in Table 
1. The location of these primers is shown in Figure 3.
Primers for sequencing the rpsL gene that encodes the S12 protein were a 
25 nucleotide reverse primer, rpsG 58R and a 25 nucleotide forward primer, rpsL 
U106F (Table 1).
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Table 1. Oligonucleotides used for sequencing the 16S rRNA gene and the 
ribosome proteins S5 and S I2.
Oligonucleotide Gene Sequence (5'-3')
rpsE U322F rpsE (S5) AAT AAAGGAC AAAAT AGGG
rpsE 441R rpsE (S5) CAAAACTAAATCAAATGCC
16SU169F 16S rRNA AATGACCTAAAATTAAGTCTAA
16S 40F 16S rRNA TTGTTACGACTTCACCCCCCTC
16S 553F 16S rRNA TCAAGCCCTGGTAAGGTTCC
16S 659R 16S rRNA GAGT AT GCTCGC AAGAGT G
16S 993R 16S rRNA CGTTGTTCGGGATTATTG
16S 1060F 16S rRNA TCATCACTTTGTCATTTC
16S 1538R 16S rRNA AAATAACGAAGAGTTTGATCC
BB425 3F 16S rRNA GGAAGATGAGAGAAGGGAAG
BB426 288F 16S rRNA AGGATT CGCCTTT GCC AAG
rpsG 58R rpsL (SI2) AATT AT AT CTGGT AT C AAC AAAAAC
rpsLU106F rpsL (SI2) AAAATTAAAGTTAGTGAAAATATCG
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j U169F—» I 40F— > | 553F— > | 1060F—>
0 | <— 659R | <—993R | <—1538R | <—BB4253F | <—BB426 288F j
16S start 16S end |
Figure 3. A map of the annealing sites for each primer. These primers were used 
in PCR to amplify 500-600 bp DNA fragments for sequencing the 16S rRNA 
gene in B. burgdorferi.
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Coumermycin Ai Resistance. Random site-directed mutagenesis was 
performed by Betsy Eggers on the T162 codon of the gyrB gene by overlap 
extension as previously described (76). Two overlapping PCR fragments were 
produced from two sets o f primers and then amplified using the flanking primers 
of the first reactions. In the first PCR, a 357 nucleotide product was amplified 
using a 24 nucleotide forward primer 14IF (5-
GGCTTTAGCTGGGTTTTGTGATAG-3') and a 27 nucleotide reverse primer 
498R/T162X (5'-AAATGAAACCTTNNNCCCCGTAACAGA-3'). A second 
497 nucleotide PCR product was amplified using a 27 nucleotide forward primer 
472F/T162X (5'- TCTGTTACGGGGNNNAAGGTTACTTTT-3') and a 24 
nucleotide reverse primer 969R (5'-GACAGAAATAACAGCTGTAAGCCC-3'). 
Sites with N (the triplet for T162) had any of the four DNA bases to yield all 
possible codons. The purified fragments were then amplified in a second PCR 
with the two flanking primers, 141F and 969R, from the initial reactions. The 
resulting PCR product, a population of DNA molecules presumably encoding all 
codons for residue 162, was purified and 5 pg of the DNA was electroporated into 
B. burgdorferi strain B31-A. The transformed culture was plated in semi-solid 
BSK medium containing 0.1 pg/ml of coumermycin Ai. (Coumermycin Ai was 
first dissolved in DMSO.) Colonies that appeared on the plates in 14 days were 
isolated and grown in liquid BSK medium containing 0.1 pg/ml coumermycin Ai. 
DNA from the cultures was extracted using standard protocols described above. A 
PCR product from the putative mutant gyrB gene was obtained using the primers
26
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14IF and 969R. The PCR product was purified by ammonium acetate 
purification and sent to the Murdock Molecular Biology Facility for sequencing.
2.2 Susceptibility
Spectinomycin Susceptibility. A susceptibility assay was done for each 
identified mutant class represented by SPR3 (C1186U) and SPR6 (All85G) as 
previously described (74, 77). Cultures were grown in 10 ml of BSK until 
108cells/ml was present. From these cultures, 106 cells, determined by an OD60o, 
were inoculated into 4 ml of BSK with the following concentrations in pg/ml of 
spectinomycin: 0, 60,120,180,240, 300, 360, and 480. After incubating at 34°C 
for 72 hours, the cultures were pelleted, resuspended in one ml o f dPBS++ and 
the ODeoo was determined. The percent growth was the ODeoo of each sample 
compared to the ODeoo of a control with no antibiotic, which was defined as 100% 
growth. This procedure was repeated four times for SPR3 and six times for 
SPR6. A susceptibility assay was also done for wild-type B. burgdorferi at 
spectinomycin concentrations in pg/ml of 0, 0.015,0.03,0.06,0.15, 0.30,0.60 
and 1.5. An IC5 0, the inhibitory concentration that prevents 50% growth at 72 
hours, was used to compare the level of resistance for the mutants. The IC50 was 
determined by graphing the results in SigmaPlot®. Susceptibility assays were 
performed on both spectinomycin-resistant mutants, SPR3 and SPR6, to test for 
cross-resistance to the antibiotics streptomycin, kanamycin and gentamicin. 106 
cells of each mutant were added to 4 ml of BSK in 10 ml tubes. Antibiotics were 
added at the following concentrations in pg/ml and the cultures incubated for 72
27
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hours at 34°C: streptomycin, 0,0.7,1.8, 3.5, 7,18, 35,70; kanamycin, 0, 0 .8 ,2 ,4 , 
8,20,40, 80; and gentamicin, 0,0.6,1.5, 3, 6,15, 30, 60. An ODeoo was taken for 
each culture tube to determine the percent growth and plotted in SigmaPlot® to 
determine the IC50 for each mutant in each antibiotic.
To determine if  the spectinomycin-resistant mutation was dominant or 
recessive, a plasmid expressing the mutant SPR3 (Cl 186U) 16S rRNA gene was 
constructed. The plasmid vector, pBSV2RII (Figure 4), was derived from pBSV2 
(78) by removing the EcoRl restriction site in open reading frame 2 (ORF2) (S. 
Bundle and D.S. Samuels, unpublished data). The 16S rRNA gene was amplified 
from SPR3 using the proofreading polymerase KOD. The primers used in the 
PCR were 16S U169F and 16S 1538R (Table 1). The approximately 1.7 kb PCR 
product includes the entire 16S rRNA gene with its promoter. A 3' adenine 
overhang was added to the KOD polymerase PCR product with Taq polymerase. 
The overhang reaction was incubated for 10 minutes at 12° C. The adenine 
overhang is required for cloning into the pCR2.1-TOPO plasmid. The fragment 
was cloned into pCR2.1 using a TOPO TA cloning kit (InVitrogen®). The 
pCR2.1 plasmid was transformed into E. coli TOPIO F' cells and extracted from a 
10 ml culture using a WizardPlus® mini prep kit. The 1.7 kb 16S rRNA gene 
insert was removed from pCR2.1 with EcoRl and ligated into the single £coRI 
site of pBSV2RII, yielding plasmid pVSPR3. The plasmid was transformed into 
E. coli DH5a cells, which were grown on 40 pg/ml kanamycin plates to select for 
the plasmid. Colonies from the plates were PCR-screened for the presence of the 
plasmid and insert using the primers to construct the insert (16S U169F and 16S
28
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1538R). Plasmid DNA was purified with a Wizard Plus® midi prep kit and 5 pg of 
each plasmid was electroporated into competent B. burgdorferi strains B31-F and 
B31-A as described (75). These cells were plated in semi-solid BSK medium with 
40 pg/ml of kanamycin. When colonies appeared, they were picked and grown in 
liquid BSK with 160 pg/ml of kanamycin to continue selective pressure. To verify 
the presence of the pBSV2RH and pVSPR3 plasmids in B31-A and B31-F, DNA 
was extracted from the cultures (as previously described) and 2 pg was 
transformed back into E. coli DH5a. DH5a was plated on Luria-Bertani plates 
with 40 pg/ml kanamycin to screen for colonies with the respective plasmid that 
was present in the B31-F DNA extraction.
Susceptibility assays were done as described to determine the level of 
resistance conferred by each of the constructed plasmids in wild-type and SPR3 
cells. The SPR3 16S rRNA gene was sequenced to check for mutations other than 
the C l 186U previously identified as spectinomycin resistant. The 16S U169F 
primer was used to sequence the 5' end, BB426 288F was used to sequence the 3' 
end, and 553F was used to sequence the center of the SPR3 16S rRNA gene 
(Table 1).
To confirm if  the SPR3 16S rRNA gene was expressed from the 
pBSV2RII plasmid in B31-F, sequencing of cDNA was done using the following 
protocols from strain B31-F/pVSPR3 to evaluate the amount of mutant RNA 
present in the cell. A culture containing 1010 cells of strain B31-F/pVSPR3 was 
centrifuged at 8000 rpm for 15 minutes to pellet the cells. The pellet was 
resuspended in 4 ml of TRIzol™ and incubated for 5 minutes at ambient
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temperature. 1 ml of chloroform was added and incubated for 2.5 minutes. The 
mixture was centrifuged at 10,000 rpm for 15 minutes and the top layer 
containing RNA was transferred to a separate culture tube. RNA was precipitated 
by adding 1 ml o f isopropanol, mixing by inversion, and incubating at ambient 
temperature for 10 minutes. RNA was pelleted by centrifuging at 12,000 rpm for 
10 minutes. The pellet was washed with 75% ethanol, centrifuged again and air 
dried for 10 minutes. The final RNA pellet was resuspended in 25 ml of RNase- 
free water. An OD26 0  was taken to determine the concentration o f RNA.
The following procedures were used to obtain cDNA from the RNA. To 
insure no DNA was present, the RNA was treated with DNase RQ1 (Gibco). 5 pg 
of the treated RNA, 2 pi of random decamers, and 2 pi of water from a 
RETROscript™ RNA kit (Ambion) were incubated at 85°C for 3 minutes. 10 pi 
of this reaction was added to 2 pi of 10X RT-Buffer, 4 pi dNTP (25nm), 1 pi 
RNase inhibitor and 2 pi of Reverse Transcriptase (RETROscript™) to transcribe 
cDNA. This reaction was incubated at 44°C for one hour. The reaction was 
stopped by incubating at 92°C for 10 minutes. A PCR was performed using the 
primers 659R and 40F as described above and the product was sent to the 
Murdock Molecular Biology Laboratory for sequencing.
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Figure 4. The pBSV2RII plasmid used as a cloning vector for the SPR3 16S 
rRNA gene. The 16S rRNA gene from SPR3 with the Cl 186U mutation was 
cloned into the EcoRl site in the multiple cloning site. The plasmid was 
transformed into B. burgdorferi strain B31-F to test for spectinomycin-resistance 
of the resulting merodiploid.
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Aminoglycoside Susceptibility. A susceptibility assay was done to 
determine the level of resistance of the KanR mutant. Culture tubes were “set up” 
the same way as the spectinomycin experiment with the following concentrations 
in pg/ml of kanamycin: 0,160, 320,400, 640, 800,960 and 1120. After 72 hours 
the cells were centrifuged, resuspended in dPBS++, and an ODeoo was taken to 
determine the I C 5 0 .  Susceptibility assays were also performed to test for cross­
resistance to spectinomycin, streptomycin, and gentamicin. Again, 106 cells of 
the mutant were added to 4 ml of BSK, grown for 72 hours at 34°C with the 
following concentrations in pg/ml added to individual tubes: spectinomycin, 0, 
0.015, 0.03, 0.06, 0.15, 0.3, 0.6, 1.5; streptomycin, 0, 0.7, 1.8, 3.5, 7, 18, 35, 70; 
and gentamicin, 0, 0.6, 1.5, 3, 6, 15, 30, 60. The amount of gentamicin used in 
this assay was increased to 0,120,180,240, 300, 360,480, and 600 as a result of 
the resistance at lower levels. To determine the increase in resistance to both 
kanamycin and gentamicin, a wild type B31-A culture was assayed at the 
following concentrations in pg/ml: kanamycin; 0, 0 .8 ,2 ,4 , 8 ,20,40, 80; 
gentamicin; 0, 0.6,1.5, 3, 6,15, 30, 60; and streptomycin; 0, 0.7,1.8, 3.5, 7,18, 
35, 70.
Susceptibility assays of the two streptomycin-resistant mutants SmR3 
(K88R) and SmR4 (K88E) were performed as described with the following 
concentrations in pg/ml of streptomycin: 0, 70, 140, 210, 280, 350, 420, and 490. 
Susceptibility assays were also done to test for cross-resistance to the other three 
antibiotics.
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Coumermycin Ai Susceptibility. A susceptibility assay, as described for 
the other antibiotic-resistant mutants, was performed on each of the coumermycin 
Ai-resistant T162 mutants to determine the level of resistance (IC50). These assays 
included a naturally occurring T162I mutant that was previously isolated (D.S. 
Samuels, unpublished data). B. burgdorferi strain B31-A was also assayed to 
determine the wild-type level of resistance to coumermycin Ai. The 
concentrations in pg/ml of coumermycin Ai added to the B31-A cultures were: 0, 
0.01, 0.025, 0.05,0.1, 0.25, and 0.5. 1.0. Because coumermycin Ai is dissolved 
in DMSO, the protocol was modified to add equal amounts of DMSO to each 
culture tube in the assay, but not to exceed 1% (40 pi) of the total volume. At 
high levels of coumermycin Ai, the culture tubes had to be vortexed and warmed 
to 34° C to prevent coumermycin Ai from precipitating out of solution. Each 
culture in the assay was grown to 107 to 108 cells/ml before an OD6 00 was taken, 
which took 4-6 days. The identified mutants were assayed for coumermycin Ai 
resistance at levels found in Table 2.
2.3 Metabolism of Antibiotic-Resistant Mutants
Competition Assays. An in vivo competition assay between wild-type 
B31-A and the mutant antibiotic resistant strains similar to the experiment done 
by Moine et al. was performed (79). Cultures of B. burgdorferi strains B31-A, 
SPR3, SPR6, SmR4 and KanR/GenR were grown, without selection, in 10 ml of 
BSK to a cell density of 108 cells/ml. The concentration of cells was determined 
by a spectrophotometry reading at ODeoo- From these cultures, approximately 105
33
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cells of each strain were added to 10 ml of BSK to make the following nine 
different cultures: B31-A, SPR3, SPR6, SmR4, KanR/GenR, B31-A+SPR3, B31- 
A+SPR6, B31-A+SmR4, andB31-A+KanR/GenR. After mixing, approximately 
103 cells from each culture were plated using techniques already described to 
evaluate the number of cells in each culture at the beginning of the assay. The
o
cultures were incubated for 96 hours until a cell density o f about 10 cells was 
reached. Each time growth reached 108 cells/ml (96 hours) another 105 cells were 
passed into 10 ml of BSK. Cultures were passed 10 times, or ~ 100 generations. 
Three of the experiments included plating cultures at 5 passages in addition to the 
five sets of plates that were made after 10 passages to determine if  the mutants 
were still present with wild-type strain B31-A after 50 generations. At the end of 
the assay, 103 cells from each of the nine different cultures were plated into semi­
solid BSK medium with no antibiotic and in BSK plates with the appropriate 
antibiotic to screen for the ratio o f antibiotic-resistant colonies to the wild-type. 
The first two sets of competition assay experiments were plated using the same 
method described above for plating B31-A on plates with spectinomycin, 
streptomycin and kanamycin to search for strains resistant to these antibiotics 
(74). The last two competition assays were plated using the following technique 
(80): Two parts BSK were added to one part 2% agarose after equilibrating both 
at 55°C. 15 ml of the BSK-agarose medium was pipetted onto 100 mm plates. 
After this layer solidified, 20 ml of molten media at 42°C was mixed with the 
appropriate B. burgdorferi strain and pipetted on top of the solidified 15 ml. An 
example of the procedure for adding cells to both methods of plating was as
34
with permission of the copyright owner. Further reproduction prohibited without permission.
follows: 103 cells of SPR3, SPR6, B31-A + SPR3 and B31-A + SPR6 cultures 
were plated with no antibiotic or with 30 pg/ml spectinomycin to determine the 
number of spectinomycin mutants relative to the wild-type. This was done with 
each strain on plates without selection and on plates with their respective 
antibiotic. The plates were incubated for two weeks at 34°C at which time the 
colonies on each plate were counted. This experiment was repeated five times.
At the end of the last growth assay, 20 colonies were picked from the B31- 
A+SPR3 plate with no selection and 20 colonies were picked from the B31- 
A+SPR6 plate with no selection. Each of these colonies was added to one of the 
wells in a 24-well culture dish containing 2 ml BSK with 30 pg/ml of 
spectinomycin. SPR3 mutants were added to three of the wells in the B31 - 
A+SPR3 dish for a positive control and no cells were added to one of the wells to 
serve as a negative control. SPR6 mutants were added to three o f the wells in the 
B31-A+SPR6 dish and one well had no cells added. A color change from red to 
yellow caused by an increase in acidity from the metabolic activity of the B. 
burgdorferi strains was used to determine if  the well was positive or negative for 
spectinomycin- resistant mutants.
Growth Assay. A simple growth assay was performed to determine the 
doubling time of the respective mutants compared to wild-type B31-A (81). As 
with the competition assay, each of the strains (B31-A, SPR3, SPR6, SmR4, and 
KanR/GenR) was grown in 10 ml of BSK until a concentration of 108 cells/ml 
was reached. From these cultures, 106 cells of each strain were added to separate 
tubes containing 50 ml of BSK. Every 24 hours for three days, 10 ml of each
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culture were removed and an OD600 was taken to determine the number of 
cells/ml. The doubling time, when cells were in exponential growth phase, was 
calculated using the following equation for the growth between day 1 and 2: 
T , - T i  
log2C2/Ci
Where, T2 -  Ti represents the time difference between day 2 and day 1, which was 
24 hours. C2/Ci represents the concentration of cells on day 2 and day 1. This 
procedure was repeated three times. The growth rates were plotted using 
SigmaPlot®, and a student’s t-test using SigmaPlot ® was performed to evaluate 
the significance of the differences in doubling times of each strain.
A growth assay was done to determine the doubling time of the 
coumermycin Ai-resistant mutants following the same procedure described for 
the spectinomycin and aminoglycoside-resistant mutants.
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Table 2. Concentrations of coumermycin Ai used in susceptibility assays for each 
T162 mutant.
Mutation Coumermycin A i pg/ml
T162I 0 ,1 ,2 , 5,10,25, 50,100
T162M 0, 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0
T162F 0, 50,100,150,200,300,400, 500
T162S 0, 0.25, 0.5,1.0, 2.5, 5.0, 10,25
T162L 0,10, 25, 50, 100,150, 200, 250
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Chapter 3 
Spectinomycin-Resistant and Aminoglycoside-Resistant Mutants
3.1 Identification and Characterization of Spectinomycin-Resistance Mutants
In an effort to develop a new selectable marker for manipulating the B. 
burgdorferi genome, Frank et al. discovered a high frequency of background 
mutants on 1.5 pg/ml spectinomycin plates, which precluded using the antibiotic 
for selection (77). A number of other bacteria have been identified with 
mutations conferring spectinomycin resistance so we hypothesized that B. 
burgdorferi strain B31-A may harbor a large subpopulation with the same type of 
mutation. With this knowledge we set out to identify and characterize the source 
of the large number of spectinomycin-resistant mutants.
Spectinomycin Mutation Frequency. The frequency of the 
spectinomycin-resistant mutants was determined by plating B. burgdorferi in 
three different concentrations of spectinomycin: 1.5 pg/ml, 6.0 pg/ml and 30 
pg/ml which are 7,29 and 143-fold higher than the concentration that inhibits
Q  7
growth of the wild-type by 50%. 10 and 10 strain B31-A cells were plated at 
each of these concentrations and colonies typically appeared within 11 days.
R •When 10 B31-A cells were plated, an average of 572, 694, and 514 colonies 
grew in spectinomycin concentrations o f 1.5, 6.0 and 30 pg/ml, respectively. 
Similar results were achieved when 107 cells were plated, producing an average of 
69, 62 and 62 colonies in 1.5,6.0 and 30 pg/ml spectinomycin, respectively.
These procedures were repeated at least four times with the results shown in
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Table 3. The frequency of spectinomycin mutants in the B. burgdorferi 
population is ~ 6 x 10‘6.
To test the hypothesis that there was a high rate of mutation that confers 
resistance to spectinomycin, three spectinomycin plates were inoculated with 108 
cells of a recently isolated clone, the kanamycin and gentamicin-resistant mutant 
(KanR/GenR), with a known 16S rRNA sequence that did not include a mutation 
specific for spectinomycin-resistance (Figure 5). No colonies grew on any of the 
three plates inoculated with KanR/GenR mutants suggesting that the high 
frequency of spectinomycin-resistant mutants was due to a large subpopulation 
and not a high mutation rate. Therefore, we hypothesized the mutant had a low 
fitness cost so that it would be maintained in the population.
Identification of the Spectinomycin-Resistant Mutations. 
Spectinomycin-resistant mutations have been mapped to the 16S rRNA gene in 
other bacteria (11,13). Using this information we sequenced the 16S rRNA gene 
in seven of the spectinomycin-resistant mutants to determine the mechanism of 
resistance. Results of the sequencing revealed that three mutants, SPR5, SPR6 and 
SPR7 had an 16S rRNA gene T354C mutation resulting in a 16S rRNA AI 185G 
mutation. The other four mutants, SPR1, SPR2, SPR3 and SPR4, had a G353A 
16S rRNA gene mutation resulting in a Cl 186U 16S rRNA mutation (Figure 5). 
The Cl 192U spectinomycin-resistant mutation is homologous to the site 
identified in spectinomycin-resistant E. coli and T. thermophilus (11,13), while 
the AI 185G mutation is homologous to that found in C. reinhardtii (26) and has 
not been previously described in bacteria. The 1185-1186 16S rRNA sites are
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located in helix 34 that can be seen in Figure 6 . The sequence reveals no 
compensatory mutations at the based-paired partners G1058 (1186) and U1059 
(1185) (data not shown), which correspond to E. coli sites G1064 and U1065. The 
rpsE gene encoding the S5 protein was also sequenced and no mutations were 
found at sites 60-66 where spectinomycin-resistant mutations are typically found 
(Figure 7) (11, 24).
Antibiotic Resistance. Susceptibility assays with wild-type B. burgdorferi 
strain B31-A, SPR3 (Cl 186U), and SPR6  (A1185G) revealed that both mutations 
confer a high level of resistance to spectinomycin. The IC50  for wild-type B. 
burgdorferi is 0.2 pg/ml spectinomycin. The Cl 186U mutant, SPR3, has an IC50  
of -300 pg/ml for a 1500-fold increase in resistance to spectinomycin. The 
A1185G mutant, SPR6 , has an IC50 greater than 500 pg/ml, making it >2500 
times more resistant than the wild-type (Figure 8  and Table 4).
SPR3 and SPR6  show no high levels of cross-resistance to related 
antibiotics, streptomycin, kanamycin and gentamicin (Figures 9, 10, 11 and Table 
4). The I C 5 0  for wild-type B. burgdorferi strain B31-A is 11 pg/ml, 9 pg/ml, and 
2.5 pg/ml for streptomycin, kanamycin, and gentamicin, respectively. 
Aminoglycoside-resistance levels for B31-A used in these assays to compare 
cross-resistance were nearly identical to those reported previously (77). Both 
streptomycin and kanamycin had an I C 5 0  of 7 pg/ml determined previously (77), 
which is slightly lower than the 11 pg/ml and 9 pg/ml, respectively, determined in 
this study (Table 4). The I C 5 0  for SPR3 was 6  pg/ml, 17 pg/ml, and 2.5 pg/ml for 
streptomycin, kanamycin, and gentamicin, respectively. The I C 5 0  for SPR6  was
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9,13 and 2.5 (ig/ml, respectively, for the same set of antibiotics. The results from 
all of the antibiotic-resistance assays for SPR3 and SPR6 are summarized in Table
4.
A merodiploid was constructed to test the dominance of the 
spectinomycin-resistant mutant using the pVSPR3 plasmid, constructed from 
pBSV2RII and the Cl 186U mutant 16S rRNA. Sequencing this plasmid identified 
no additional mutations. Because of difficulties in cloning pVSPR3 into strain 
B31-A, which is the strain used throughout these experiments, a closely related 
but more transformable strain, B31-F, was used. Susceptibility assays revealed no 
increase in spectinomycin resistance when pVSPR3 was present in B31-F. Four 
different colonies were used in the susceptibility assays of B31-F with pVSPR3 
and the results from all the susceptibility assays with these plasmids are listed in 
Table 5. Sequencing the cellular 16S rRNA in strain B31-F/pVSPR3 showed only 
wild-type 16S rRNA present in the cell, suggesting that mutant 16S rRNA was 
not being transcribed from the plasmid, which explains the lack of a resistant 
phenotype.
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Table 3. The frequency of spectinomycin-resistant mutations in B. burgdorferi 











1.5 10* 572 (± 83) 5.7 x 10'6
1.5 107 69 (± 22) 6.9 x 10'°
6.0 108 694 (± 126) 6.9 x 10'b
6.0 107 62 (± 21) 6.2 x 10'°
30 108 514 (±118) 5.1 x 10’b
30 107 62 (± 5) 6.2 x 10'6
The experiment was repeated four times for all spectinomycin concentrations with 
the exception of the 30 pg/ml with 108 cells, which was repeated seven times.
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Figure 5 . 16S rRNA gene sequences for seven mutant colonies picked from 
spectinomycin plates and four other aminoglycoside-resistant mutants. Wild-type 
B. burgdorferi strain B31-A sequence is on the top row. The DNA mutations are 
a G353A in SPR 1-4 corresponding to a 16S rRNA Cl 186U and a T354C 
mutation in SPR 5-7 corresponding to a 16S rRNA A1185G. Kanamycin (KAN1, 
3 and 4) and gentamicin (GEN2) resistant mutants have no mutations in this 
region.
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Figure 6. 16S rRNA secondary structure map of the helix 34 region (boxed). 
Both spectinomycin-resistant mutations are in helix 34. Modified from: 
www.ma.icmb.utexas.edu/ (9)
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Figure 7. SPR1, SPR2, SPR3 and SPR6 rpsE gene sequences that encode the 
ribosomal S5 protein. These spectinomycin-resistant mutants have no mutations 
in the 60-66 nucleotides that are known to confer spectinomycin-resistance in 
other bacteria.
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Figure 8. Spectinomycin susceptibility assay of the two mutants SPR3 (Cl 186U) 
and SPR6 (A1185G). Percent growth was determined from a spectrophotometer 
reading at ODeoo- Error bars represent the SEM. B31=B31-A. n = 5 for B31 and 4 
for SPR3 and SPR6.
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Figure 9. Streptomycin susceptibility assays for SPR3, SPR6, and KanR/GenR. 
This plot, from the susceptibility assays to determine cross-resistance to 
streptomycin, shows that the spectinomycin-resistant mutants SPR3 and SPR6 
and the kanamycin/gentamicin-resistant mutant KanR/GenR, are not resistant to 
streptomycin. The percent growth was determined from a spectrophotometer 
reading at OD60 0 and the error bars represent the SEM. B31=B31-A. n = 3 for 
B31 and KanR/GenR and, 6 for SPR3 and SPR6.
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10 20 30 40 50 60
ug/ml Kanamycin
70 80 90
Figure 10. Kanamycin susceptibility assays for SPR3 and SPR6. This graph, 
from the susceptibility assays for cross-resistance to kanamycin of the Cl 186U 
(SPR3) and A1185G (SPR6) shows only a slight increase in resistance to 
kanamycin. The percent growth was determined from a spectrophotometer 
reading at OD60 0  and the error bars represent the SEM. B31=B31-A. n = 3 for 
B31, SPR3 and SPR6.
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10 15 20
ug/ml Gentamicin
Figure 11. Gentamicin susceptibility assays for SPR3 and SPR6. This graph 
shows no increase in resistance to gentamicin in the SPR3 Cl 186U and SPR6 
A1185G mutants. The percent growth is from a spectrophotometer reading at 
OD60 0  and the error bars represent the SEM. B31=B31-A. n = 3 for B31, SPR3 
and SPR6.
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Table 4. The IC50 (pg/ml) for each of the antibiotic-resistant strains to four 
antibiotics.
Strain Mutation Sp1 Sm1 Km1 Gm1
B31-A None 0.22 11 9 2.5
SPR3 16S rRNA Cl 186U 300 6 17 2.5
SPR6 16S rRNA A ll85G >500 9 13 2.5
KanR/GenR 16S rRNA A1402G 0.12 6 >800 >600
SmR3 S12K88R 0.10 80 13 1.5
SmR4 S12K88E 0.08 110 16 1.5
1Antibiotics: spectinomycin (Sp), streptomycin (Sm), kanamycin (Km), and 
gentamicin (Gm).
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Table 5. The susceptibility assays and resulting levels of resistance of the 16S 
rRNA merodiploid.





B31-A + pBSV2RIIa 0.2 1
B31-F + pVSPR3b 0.2 1
aThe pBSV2RII plasmid does not have a gene for 16S rRNA.
bThe pVSPR3 plasmid contains a 16S rRNA gene with the G353A mutation
(C1186U 16S rRNA mutation).
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3.2 Identification and Characterization of Aminoglycoside Resistant Mutants
The high frequency of spectinomycin-resistant mutants identified in our 
studies motivated us to examine the frequency and mechanism of resistance to 
closely related aminoglycoside antibiotics. The maintenance of spectinomycin- 
resistant mutants at high frequency indicates that there is a low fitness cost for 
these mutants. The structurally similar aminoglycosides were tested to discover if 
there is a corresponding fitness cost associated with the frequency of these 
mutations. Identification of the frequency and levels of resistance for these 
mutants may also aid in choosing reliable selectable markers when working with 
B. burgdorferi. Already, several markers have been constructed with 
aminoglycoside resistance cassettes for identifying clones of interest (77, 78, 82). 
Identifying and characterizing the frequency of aminoglycoside resistant strains 
should aid in choosing the appropriate plasmids for manipulating the Borrelia 
genome.
Identification of Kanamycin and Gentamicin Resistant Mutations.
The frequency of kanamycin resistance was determined by plating 107, 108 and 
109 cells of B. burgdorferi strain B31-A in semi-solid BSK medium containing 40 
pg/ml kanamycin. Based on these results, the frequency of this mutation is 
between 1.3 x 10'8 and 1.4 x 10'7. Kanamycin plates that had 108 cells added 
produced 3-28 colonies. 109 cells plated five times produced an average of 13 
colonies per plate (ranging from 3 to 29 colonies per plate). Colonies took 14 days 
to appear on the kanamycin plates, which is three days longer than the appearance 
of spectinomycin-resistant colonies to appear on spectinomycin plates. Plating
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B31-A on gentamicin plates gave similar results. The frequency of gentamicin- 
resistant colonies was 1 x 10'8 when 109 cells were plated in 30 pg/ml of 
gentamicin. Results from these experiments are compiled in Table 6.
To determine the location of the mutation that conferred resistance to 
kanamycin and gentamicin, three colonies were isolated from kanamycin plates 
and grown in liquid BSK medium with 40 pg/ml of kanamycin and one colony 
from the gentamicin plate was grown in liquid BSK medium with 25 pg/ml 
gentamicin. Sequencing of the 16S rRNA gene revealed an A1402G mutation in 
each of the clones designated KAN1, KAN3, and KAN4 (Figure 12), which 
corresponds to the A1408G mutation in E. coli conferring resistance to kanamycin 
and gentamicin (36). Sequencing the 16S rRNA gene from a colony grown on 
plates containing 30 pg/ml of gentamicin identified the same mutation, A1402G, 
conferring resistance to gentamicin (Figure 12 and Table 4). The gentamicin- 
resistant strain GEN2 has an identical 16S rRNA sequence as the kanamycin- 
resistant strain making a single designation, KanR/GenR, convenient for the 
kanamycin- and gentamicin-resistant mutant carrying the A1402G mutation. 
Because the kanamycin-resistant mutants and the gentamicin-resistant mutant had 
identical sequences they are represented by KanR/GenR in this paper. The 
location of the A1402G mutation is in helix 44 as shown in Figure 13.
Antibiotic Resistance. The KAN3 mutant, now designated KanR/GenR, 
was assayed for susceptibility to kanamycin and the other antibiotics. The results 
of this assay, which are graphed in Figure 14, reveal an IC50 > 800 pg/ml, which 
is more than 90 times the wild-type level o f resistance to kanamycin (Table 4). As
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expected a susceptibility assay revealed that the kanamycin-resistant mutant was 
also cross-resistant to gentamicin at high levels. The I C 5 0  for the KanR/GenR 
A1402G mutant is over 600 pg/ml of gentamicin, which is 240-fold more 
resistant than wild-type B31 -A (Figure 15). The I C 5 0  of the KanR/GenR mutant 
in gentamicin steadily decreases to 75% of wild-type at 360 pg/ml then increases 
to nearly 90% of the wild-type at 600 pg/ml (Figure 15). The cause of this 
increase in I C 5 0  is unknown.
In addition to the susceptibility assays done to determine the level of 
resistance to kanamycin, assays were done to identify cross-resistance to the 
antibiotics streptomycin, and spectinomycin. The assays reveal that the A1402G 
mutation provides no resistance to spectinomycin or streptomycin. The I C 5 0  for 
the KanR/GenR A1402G mutant is 0.12 pg/ml spectinomycin (Figure 16) and 6 
pg/ml streptomycin (Figure 9), which is similar to wild-type B31-A (Table 4).
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Table 6. The frequency of aminoglycoside-resistant mutants.
Antibiotic Concentration
(Pg/ml)




Spectinomycin 30.0 10s 514 (± 118)a 5.1 x 10'b
Spectinomycin 30.0 107 62.0 (± 5 )b 6.2 x 10’b
Kanamycin 40.0 10y 13.2 (± 4.3)c 1.3 x 10'*
Kanamycin 40.0 10s 14.0 (± 6) b 1.4 x 10'7
Streptomycin 35.5 10y 3.4(± 1.7)c 3.4 x 10'y
Streptomycin 35.5 10* 2.0 (± l ) c 2.0 x 10’*
Gentamicin 30.0 109 10.3 (±1.2) d 1.0 x 10'*
an = 7 
bn = 4 
cn = 5 
dn = 3
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Figure 12. 16S rRNA gene sequences from three kanamycin-resistant mutants, 
seven spectinomycin-resistant mutants and one gentamicin-resistant mutant. 
Wild-type B. burgdorferi sequence is on the top row. The DNA mutation is a 
T137C in KAN 1, 3 and 4, and in GEN2 corresponding to a 16S rRNA A1402G 
mutation. Sequences for the four kanamycin- and gentamicin-resistant mutants are 
identical for the rest of the 16S rRNA gene.
56
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
_ A  U A A U U A U  U
G I I I • I I I
G A U U G A U A u a Gq ' / ^
U - A
U C - G f J
G — C  U G
U \  u
g c a c a c u u ^ I a  ■ 
. . . . . . UU-A
g c \ V a a u u g - c a





uG G G  G C U C G
I • I -III
C U C .  U GA  G A
A .  a A A g
A/G/G a a  u u G  a c g gg g g c c c
C G U G U G
GOA
C A  A
a c A A G  \ N  u A 
II '  A
U Q
uucG^Ccu 11 11 •  • 11111 





U A G C C G U A C U  G 
i I I I I * II I ? 
G U C G G C G U G A A  
G
A 0  G
A1402G
G •  GI GU AG,
• C A  UA'
Borrelia burgdorferi
(M88329)
1. Bacteria 2. SpirochaetaleS. Spirochaetc 
4. Borrelia 5. Borrelia burgdorferi group 
November 1999
Figure 13. 16S rRNA secondary structural map of the helix 44 region. The 
A1402G mutation conferring resistance to kanamycin and gentamicin is in helix 
44. Modified from: www.ma.icmb.utexas.edu/ (9)
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Figure 14. Kanamycin susceptibility assay for KanR/GenR. The percent growth 
was determined by a spectrophotometer reading at ODgoo- Error bars represent 
the SEM. B31=B31-A. n = 3 for B31 and KanR/GenR.
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Figure 15. Gentamicin susceptibility assay for KanR/GenR. The percent growth 
was determined from a spectrophotometer reading at ODeoo- Error bars represent 
the SEM. B31=B31-A. n = 3 for B31 and KanR/GenR.
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Figure 16. Spectinomycin susceptibility assay for aminoglycoside-resistant 
mutants. The percent growth was determined from a spectrophotometer reading at 
OD60o- Error bars represent the SEM. B31 =B31 -A. n = 5 for B31 and 3 for 
KanR/GenR, SmR3 and SmR4.
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Identification of Streptomycin-Resistant Mutants. The frequency of 
streptomycin resistance is 2.0 x 10'8 to 3.4 x 10'9, based on the number of colonies 
that grew on BSK plates containing 35 pg/ml of streptomycin (Table 6). BSK 
plates with 108 cells typically had one-two colonies, while plates with 109 cells 
ranged from 3-9 colonies. Colonies appeared within 11 days after plating.
Sequence analysis of the four streptomycin-resistant mutants, designated 
SmRl, SmR2, SmR3, and SmR4, revealed two different mutations in the rpsL 
gene encoding the S12 protein (Figure 17). An A263G rpsL mutation in SmRl, 
SmR2, and SmR3 resulted in a K88R substitution in the S12 protein in each of 
these strains (Figure 18 and Table 4). An A262G mutation in the rpsL gene 
resulted in a K88E substitution in the S12 protein of SmR4 (Figure 18 and Table 
4).
Antibiotic Resistance. Susceptibility assays revealed a slight difference 
in the resistance conferred by these two mutations. The IC50 was 80 pg/ml for the 
SmR3 mutant (K88R), and 110 pg/ml for the SmR4 mutant (K88E) (Figure 19 
and Table 4). Complete sequencing of the 16S rRNA gene revealed no mutations 
in these streptomycin-resistant strains (data not shown). Ten different primers 
were used to sequence the entire gene on both strands to identify any possible 
additional mutations (Figure 4).
Susceptibility assays for spectinomycin, kanamycin, and gentamicin 
showed small changes in cross-resistance for SmR3 or SmR4. These two 
streptomycin-resistant mutants are slightly more susceptible to spectinomycin and 
gentamicin than wild-type B31-A. The IC50 in pg/ml of SmR3 for spectinomycin,
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kanamycin and gentamicin was 0.10,13, and 1.5, respectively. The IC50 of SmR4 
for the same three antibiotics was 0.08,16 and 1.5 pg/ml, respectively. By 
comparison, the IC50 for B31-A is 0.22 pg/ml for spectinomycin, 9 pg/ml for 
kanamycin and 2.5 pg/ml for gentamicin. The results from these assays are 
graphed in Figures 16, 20, and 21, and listed in Table 4.
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Figure 17. Nucleotide sequence of the rpsL gene encoding the S12 protein in 
streptomycin-resistant mutants SmRl, SmR2, SmR3 and SmR4. Wild-type B31- 
A is the top line. SmR4 has an A262G mutation and SmRl-3 have an A263G 
mutation corresponding to a K88E and K88R amino acid substitution in the 
ribosome S12 protein, respectively.
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Figure 18. Amino acid sequences for the S12 protein in SmR3 and SmR4. Wild- 
type B31-A has lysine (K) at residue 88 while the SmR3 mutant has an arginine 
(R) substitution and SmR4 has a glutamic acid (E) substitution.
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Figure 19. Streptomycin susceptibility assay for SmR3 and SmR4. The percent 
growth was determined by a spectrophotometer reading at ODeoo and the error 
bars represent the SEM. B31=B31-A. n = 3 for B31, SmR3 and SmR4.
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Figure 20. Kanamycin susceptibility assay for SmR3 and SmR4. The percent 
growth was determined from a spectrophotometer reading at ODgoo and the error 
bars represent the SEM. B31=B31-A. n = 3 for B31, SmR3 and SmR4.
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Figure 21. Gentamicin susceptibility assays for SmR3 and SmR4. The percent 
growth was determined from a spectrophotometer reading at OD600 and the error 
bars represent the SEM. B31=B31-A. n = 3 for B31 and SmR4. n = 5 for SmR3.
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3.3 Competition and Growth Assays
The frequency of spectinomycin-resistant mutants in the B31-A 
population was approximately 100-fold higher than the frequency of the 
aminoglycoside-resistant mutants. We hypothesized that this difference was a 
result of a lower fitness cost of the SPR3 (Cl 192U) and SPR6 (A1185G) 
mutations conferring spectinomycin resistance. This lower fitness cost enables 
spectinomycin-resistant mutants to compete well enough with wild-type B31-A to 
be maintained at frequencies higher than the typical mutation frequency observed 
for most bacteria. To test this hypothesis, growth and competition assays were 
done with B31-A and four of the mutants.
Growth Assays. Three independent growth assays resulted in no 
significant differences in doubling time for the mutants and wild-type B31-A.
The doubling time was calculated during log phase growth that took place 
between day one and day two (Figure 22). From these experiments, the doubling 
time for B31-A was calculated as 7.9 hours while the doubling time was 8.8 hours 
for KanR/GenR, 8.1 hours for SPR3 and SPR6, and 8.0 hours for SmR4 (Table 
7). A paired t-test for each mutant versus B31-A indicates that the differences in 
doubling times are not statistically significant (p= 0.53 for SPR3, 0.77 for SPR6, 
0.96 for SmR4, and 0.30 for KanR/GenR, a= 0.05, Table 7).
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Figure 22. Growth curves of four antibiotic-resistant mutants. Growth was 
determined from a spectrophotometer reading at Oi>6oo at the start (day 0) and at 
days 1, 2 and 3. n = 5
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 7. Doubling time of four antibiotic-resistant mutants.
Strain Doubling Time (±SEM) 
B31-A = 7.9 hours
p-value
SPR3 8.1 (±0.3) 0.53
SPR6 8.1 (±0.1) 0.77
SmR4 8.0 (± 0.2) 0.96
KanR/GenR 8.8 (± 0.6) 0.30
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Competition Assays. At the start of each competition assay, 
approximately 1 0 3 cells from each culture were plated to estimate what percent of 
the competition cultures were antibiotic-resistant mutant cells compared to the 
B31-A wild-type cells. The number of colonies on plates without antibiotic 
selection versus plates with selection indicates that approximately equal numbers 
of mutant and wild-type cells were plated (Table 8 ). Comparing the percent of 
colonies that grew on selection at the beginning of the assay and the percent of 
colonies that grew on selection at the end of the assay indicates that SmR4 and 
KanR/GenR were completely outgrown between 50 and 100 generations while 
SPR3 and SPR6  were still present at 100 generations (Table 9).
The spectinomycin-resistant mutants cultured with B31-A fared much 
better than the aminoglycoside-resistant mutants, surviving in the population for 
100 generations. Comparing the number of cells from the B31-A+SPR3 cultures 
plated on selection versus no selection indicates that 18% of the cells remaining 
after 100 generations were SPR3. Since there is no selection for wild-type B31-A 
or against SPR3 cells on the plates without selection, a test was designed to 
quantify what percent of the colonies on the plates without antibiotic were SPR3. 
Twenty colonies from a B31-A+SPR3 plate with no selection were picked and 
grown in 2 ml BSK with 30 pg/ml spectinomycin to assess what percentage of the 
colonies were SPR3 on the plate without selection. The results of this experiment 
were similar to the one comparing the number of colonies on selection versus no 
selection with 4 of the 20 colonies (20%) being spectinomycin-resistant. Similar 
numbers were also obtained for the B31-A+SPR6 culture. Comparing the number
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of colonies on spectinomycin plates versus the number of colonies on plates 
without spectinomycin indicated that only 8 % of the cells in the culture were 
resistant to spectinomycin (SPR6 ) after 100 generations. Picking 20 B31- 
A+SPR6  colonies from plates with no selection and growing them in 2 ml BSK 
with 30 fig/ml spectinomycin produced two spectinomycin-resistant cultures, 
which yield 1 0 % of the colonies in the culture that are still spectinomycin- 
resistant (SPR6 ) after 100 generations. The experiment at 50 generations had 
more spectinomycin-resistant mutants present than at 1 0 0  generations, as was 
expected. Plating on selection versus no selection showed that 41% of the cells 
were SPR3 in the B31-A+SPR3 culture and 41% were SPR6  in the B31-A+SPR6 
culture. These results are listed in Table 9.
No colonies from the B31-A+KanR/GenR culture grew on plates with 
kanamycin, nor did any colonies from the B31-A+SmR4 culture appear on plates 
with streptomycin after 100 generations. However, colonies from the same 
cultures grew on plates with no selection indicating that wild-type B31-A was the 
only cell type in the culture. Plating the B31-A+SmR4 culture at 50 generations 
did produce colonies on the streptomycin plates. Two separate experiments 
produced similar results indicating that 6 % of the cells in the B31-A+SmR4 
culture were SmR4 at 50 generations of the competition assay. Less than one 
percent of the B31-A+KanR/GenR culture were KanR/GenR mutants at 50 
generations. Two independent experiments produced only one colony each on 
kanamycin plates while the two plates with no selection produced 104 and 152 
colonies from the B31-A+KanR/GenR culture.
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Single cultures used as controls for the competition assays revealed that 
each of the mutant strains, SPR3, SPR6 , SmR4, and KanR/GenR, grew on plates 
with and without antibiotic selection after 1 0 0  generations indicating that these 
cells were still viable and antibiotic-resistant (Table 10). Approximately 103 cells 
were plated.
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Table 8 . The number of colonies that grew on plates from each culture at the 
beginning of the competition assay.
Strain No Selection (±SEM) Selection (±SEM)
B31-A 411 (±24.2) 0 (±0 )
SPR3 1173 (±25.7) 837 (±35.0)
SPR6 1316(±208) 1285 (±40.0)
B31-A + SPR3 1136 (±73.9) 775 (±19.2)
B31-A + SPR6 1385(±130) 1172 (±109)
SmR4 1061 (±65.8) 836 (±89.9)
B31-A + SmR4 1178 (±86.0) 862 (±70.0)
KanR/GenR 762(±114) 918(±214)
B31-A +KanR/GenR 1072 (±4.00) 1286(±138)
Spectinomycin (30 pg/ml)was the antibiotic used for selection with all SPR3 and 
SPR6  cultures, streptomycin (35 pg/ml) was the antibiotic used for all SmR4 
cultures and kanamycin (40 pg/ml) was used for all KanR/GenR cultures. The 
chart shows that antibiotic-resistant strains are present in large numbers in the 
culture tubes at the beginning of the competition assays, n = 5.
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Table 9. The number of antibiotic-resistant cells compared to wild-type.
Strain 50 Generations (±SEM) 100 Generations 
(±SEM)
B31-A + SPR3 SPR3a 41% (±4.4)a SPR3 18% (±4.4)b
B31-A + SPR6 SPR6 41% (±2.1)a SPR6  8 % (±3.1)b
B31-A + SmR4 SmR4 6 .0 % (±2 .0 ) c SmR4 0% d
B31-A +KanR/GenR KanR/GenR 0.75% (±0.25)c KanR/GenR 0% d
an = 3 
bn = 4 
cn = 2  
d n = 5
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Table 10. The number of mutant viable colonies on plates with antibiotic and no 
antibiotic selection after 1 0 0  generations.
Strain Avg. Colonies with No 
Selection (±SEM)
Avg. Colonies on 
Antibiotic Selection 
(±SEM)
B31-A 234 (±119) 0 (±0 )
SPR3 821(±308) 940 (±95)
SPR6 8 6 6  (±189) 1079(±338)
SmR4 927 (±170) 840 (±85)
KanR/GenR 542(±132) 361 (±206)
SPR3 and SPR6  were plated in 30 pg/ml spectinomycin, SmR4 was plated in 35 
pg/ml, and KanR/GenR was plated in 40 pg/ml kanamycin for selection. B31-A 
was also plated in each one of these antibiotic concentrations and no colonies 
were found on the plates, n = 5
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Chapter 4 
Coumermycin Ai-Resistant GyrB T162 Mutants
Coumermycin Ai has been used as a model for antibiotic-resistance in 
Borrelia burgdorferi. This antibiotic targets DNA gyrase (67), a type II 
topoisomerase that introduces negative supercoiling in DNA, which relieves 
torsional stress during replication or transcription (6 8 ). Mutations in B. 
burgdorferi gyrB, a subunit of DNA gyrase, that result in amino acid substitutions 
at residue R133 confer resistance to coumermycin Ai (73). Lewis et al. predicted 
that amino acid substitutions in E. coli GyrB T165 (homologous to T 162 in B. 
burgdorferi GyrB) would result in reduced gyrase activity and resistance to 
coumarin drugs (69). We performed site-directed mutagenesis to identify 
mutations in B. burgdorferi gyrB resulting in amino acid substitutions at residue 
T162 of GyrB that would confer coumermycin Aj resistance but maintain GyrB 
function. Characterization of coumermycin Ai-resistant mutants at residue T162 
of GyrB may further elucidate B. burgdorferi gyrase structure and function.
A naturally occurring coumermycin Ai-resistant mutant designated 
CR12E, but referred to here as T162I, with a T162I substitution in GyrB was 
previously isolated (D.S. Samuels, unpublished data). Sequencing revealed a C to 
T substitution in gyrB changing the triplet for threonine at position 162 from ACT 
to ATT, which codes for isoleucine (D.S. Samuels, unpublished data). 
Susceptibility assays showed this mutant to have an IC50 for coumermycin Ai of 
21 pg/ml, which is 420-fold more resistant than the wild-type (Figure 23 and
77
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 11). Four other mutants were created using random site-directed 
mutagenesis targeting the codon for T162 in GyrB (B. Eggers and D.S. Samuels, 
unpublished data). Several different base substitutions in the gyrB gene, TTT, 
CTT, TCA, and ATG resulted in four different amino acid substitutions from 
threonine to phenylalanine, leucine, serine, and methionine, respectively at 
position T162. These mutants were designated T162F, T162L, T162S and 
T162M. The IC50 for each of these mutants was considerably higher than the 
wild-type B31, which was determined to be 0.02 pg/ml and is identical to 
previously reported levels of resistance for B31 (73, 83). The IC50 for the mutants 
ranged from 0.5 pg/ml for T162S to 300 pg/ml for T162F. T162L had an IC50 of 
200 pg/ml, T162I had an IC50 o f 21 pg/ml and T162M had an IC5 0 of 4.0 pg/ml 
(Table 11). A plot of the T162F, T162I and T162L coumermycin Ai-resistance 
assays is in Figure 23. The assays for T162S and T162M are graphed in Figure 
24.
Doubling times for each of the mutants were calculated based on the log 
phase growth that took place between days one and two after passage. These data 
show that the mutants with the highest resistance to coumermycin Ai have the 
slowest doubling times. All mutants had slower doubling times than wild-type 
B31-A (7.9 hours). The T162F and T162L mutants, which were the most resistant 
to coumermycin A i, had the slowest doubling times of 9.2 and 8.7 hours, 
respectively. The slower growth of the T162F mutant was statistically significant 
with a p-value from a t-test at 0.05. The mutants T162I, T162M, and T162S had 
doubling times of 8.6, 8.6, and 8.2 hours, respectively (Table 11). Figure 25
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shows the growth of each of the T162 mutants for three days with log phase 
occurring between days one and two. Two of the doubling times for T162F were 
determined from day two to three when the culture was log phase growth. Log 
phase growth in these two experiments did not occur until day two.
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Figure 23. Coumermycin Ai susceptibility assay of three T162 mutants. The 
percent growth was determined from a spectrophotometer reading at ODeoo and 
the error bars represent the SEM. n = 5.
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Figure 24. Coumermycin Ai susceptibility assay for two T 162 mutants. The 
percent growth was determined from a spectrophotometer reading at OD60 0  and 
the error bars represent the SEM. n = 5.
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ACT Threonine 0.02 7.9 (± 0.5)
T162I ATT Isoleucine 21 420 8.6 (± 0.3)
T162F TTT Phenylalanine 300 6000 9.2 (±0.1)
T162L CTT Leucine 200 4000 8.7 (± 0.6)
T162S TCA Serine 0.5 25 8.2 (± 0.3)
T162M ATG Methionine 4.0 80 8.6 (± 0.6)
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Figure 25. Growth curve of the GyrB T162 mutants. Growth was determined 
from a spectrophotometer reading at ODeoo- Error bars represent the SEM. n = 5.
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Chapter 5 
Discussion
The high frequency of spectinomycin-resistant colonies appearing on 30 
pg/ml spectinomycin plates in our laboratory (76) prompted an investigation to 
identify the mechanism of resistance. We hypothesized that mutations to the 16S 
rRNA or small ribosomal subunit proteins were the cause of spectinomycin 
resistance based on previous studies in other bacteria (13,24,28, 34). We 
hypothesized that the frequency of these mutants in the B. burgdorferi B31-A 
population was due to a low fitness cost. We also theorized that there were other 
mutants present in the population resistant to the related aminoglycoside 
antibiotics. We have identified five different mutations conferring high levels of 
resistance to spectinomycin, streptomycin, kanamycin or gentamicin. We have 
also characterized five different coumermycin Ai-resistant mutants. One of these 
mutants is naturally occurring and the other four were constructed using random 
site-directed mutagenesis.
5.1 Spectinomycin Resistance
Spectinomycin is an antibiotic that prevents elongation of the polypeptide 
by blocking translocation o f  the peptidyl tRNA from the A -site to the P-site 
during translation (11, 12, 13). Mutations at several sites including 1191-1193 in 
the 16S rRNA of Escherichia coli, Thermus thermophilus, and Chlamydomonas 
reinhardtii have been shown to confer resistance to spectinomycin (12,24, 26).
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These mutations provide enough instability to allow helix 34 the movement 
necessary for translocation even while spectinomycin is bound (11).
We have identified AI 185G and Cl 186U mutations (homologous to E. 
coli AI 191 and Cl 192) in Borrelia burgdorferi 16S rRNA that confer a high level 
of resistance to spectinomycin (Figure 5). Susceptibility assays show a difference 
in resistance to spectinomycin by the two mutants. The Cl 186U mutant has an 
IC5 0 of 300 pg/ml compared with an IC5 0 well over 500 pg/ml for the AI 185G 
mutant (Table 4). Sequencing the 16S rRNA gene revealed no other mutations, 
including the complementary portion of helix 34 at sites 1057-1058 (E. coli 1063- 
1064). In addition, no mutations were found in the rpsE gene encoding the S5 
protein, a site of spectinomycin-resistant mutations in other bacteria (Figure 7). 
The absence of a second mutation in these genes suggests that the difference in 
susceptibility of the two mutants to spectinomycin is due to the different 
nucleotide sites that were mutated. This also suggests that the mutants are not 
spectinomycin-dependent. Secondary mutations in Bacillus subtilis and E. coli 
have been shown to confer spectinomycin dependence when more than one 
mutation occurs in the 16S rRNA or when there is a mutation in the S5 protein in 
addition to a mutation in the 16S rRNA (84, 85). This lack of dependence was 
confirmed by the ability of SPR3 and SPR6 to grow in the absence of 
spectinomycin (Table 8).
The 1500-fold increase in resistance to spectinomycin by the Cl 186U 
mutation is similar to the resistance levels reported for Salmonella enterica, which 
is more than 500-fold resistant to spectinomycin when a homologous mutation is
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present (86). Resistance levels conferred by plasmid-borne 16S rRNA Cl 192U 
mutation in E. coli have been measured at a more modest 16-fold increase (87). 
This difference is probably due to the seven wild-type 16S rRNA genes still 
present in E. coli.
Of more interest is the AI 185G mutation that confers over 2500-fold 
resistance to spectinomycin. A homologous mutation has been identified in the 
chloroplast of the eukaryote C. reinhardtii (AI 123G, E. coli 1191) and confers a 
high level of resistance to spectinomycin (26). Why the AI 185G mutation confers 
more resistance than the adjacent Cl 186U mutation is perplexing. There are no 
other bacterial mutations at this site (E. coli 1191) to compare resistance levels 
with an 1192 mutation. Mutations deeper in helix 34 have been hypothesized to 
confer more resistance to spectinomycin than those that are closer to the surface 
(88). This may be due to conformational changes that disrupt the right side of 
helix 34 and provide the flexibility needed in helix 34 for normal ribosomal 
function when spectinomycin is bound (11, 88). This model arises from 
experiments that show a Nicotiana G1193 A mutation that caused a 30% reduction 
in protein synthesis in 80 gg/ml spectinomycin while a G1064A mutation, which 
is deeper in the helix, had only 5% reduced activity (88). This seems plausible if 
AI 185 in B. burgdorferi is deeper in the helix than Cl 186 (11). The homologous 
site in T. thermophilus appears to be deeper in the 30S subunit based on 16S 
rRNA models from high resolution crystallography (11). Another factor 
determining the level of resistance is the specific base substitution as well as the 
site of the substitution. For example, a Cl 192 A mutation confers low levels of
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resistance to spectinomycin in E. coli whereas a Cl 192 to G or U resulted in high 
levels of resistance (24). The data in this study demonstrate that a G substitution 
provides more resistance at site 1185 than a U substitution at 1186 in B. 
burgdorferi. The wild-type base at the homologous site in Euglena gracilis, and 
the blue-green algae Anacystis is a C at position 1141 and 1132, respectively (89, 
90). The wild-type C instead of a U in 16S rRNA in both of these organisms 
provides natural resistance to spectinomycin. However, Euglena is 20-fold more 
resistant to spectinomycin than Anacystis (88). Fromm et al. hypothesized that 
species-specific interactions with spectinomycin and the translocation machinery 
are likely sources of the differences observed in levels of resistance (88). All of 
these factors, the position of the base substitution on helix 34, the particular base 
at the mutated site, and the species-specific characteristics of the translational 
machinery are probably involved with the observed differences in levels of 
resistance between the two B. burgdorferi mutants, Cl 186U and Al 185G. The 
Al 185G mutation matches the resistance levels of the KanR/GenR mutants. The 
homologous kanamycin resistant E. coli A1408G mutant reduces the binding 
affinity of kanamycin and gentamicin for helix 44. The Al 185G mutation may 
also reduce the binding affinity of spectinomycin to helix 34 reducing the 
resulting in resistance levels similar to those of kanamycin resistant mutants.
Susceptibility assays with aminoglycosides revealed that both mutants, 
SPR6 (Al 185G) and SPR3 (Cl 186U), had the same susceptibility to streptomycin 
and gentamicin as wild-type B31-A. However, both were nearly twice as resistant 
to kanamycin (Table 4). The small increase in resistance may be a result of slight
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global changes along the 16S rRNA that are caused by a decrease in the stability 
of helix 34 (12,24). Many of the helices involved in antibiotic resistance have 
been shown to interact with each other as well as several 3 OS proteins during 
translation (11,91,92). The decrease in stability of helix 34, which allows 
movement in the head region o f 16S rRNA even while the rigid spectinomycin 
molecule is bound, has been postulated to create changes in the position of helix 
28, 35, 36, and the S5 protein (11). These structural changes could, in turn, cause 
minor shifts in the position of other helices such as helix 27 and helix 44, which 
binds kanamycin, resulting in the small increase in resistance to kanamycin. All 
three helices, H27, H34 and H44 are structurally very close to each other and all 
three interact with the S5 protein either directly or indirectly (11,91,92). Helix 
27 stacks on helices 1 and 28 and the conformational switch that is made by H27 
has been postulated to change the packing interactions between these three helices 
(11,49). Because of the helix-helix interaction between H34 and H28, any 
change in the conformation of H34 due to base substitutions may affect the 
packing of the helices of the H27 switch mechanism involving HI, H27 and H28. 
One model proposes a series of switches involving H34 and H44 as a result of the 
activities of the H27 switch (11). Therefore, modifications to any of these helices 
may cause slight alterations in the functioning of the other helices that are 
contacted. Slight changes in susceptibility to antibiotics due to a mutation in a 
helix that is not associated with resistance to that antibiotic may be mediated 
through helix-helix interactions or the S5 protein, which interacts with all three 
helices involved in spectinomycin and aminoglycoside resistance.
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The frequency of the spectinomycin-resistant phenotype is 6 x 10'6 in our 
population of B. burgdorferi strain B31-A. This frequency includes both the 
Cl 186U and A l 185G mutations. The frequency of individual mutations was not 
determined since both of the mutant types appear on plates used to derive 
mutation rates. Additional point mutations in the 16S rRNA gene, which have 
been identified in other organisms conferring spectinomycin-resistance (12, 26,
27, 34), may contribute to the phenotypic mutation rate as well, but were not 
represented in the seven mutants sequenced. The same number of recently cloned 
B. burgdorferi with a known 16S rRNA gene sequence (KanR/GenR, Figures 5 
and 12) were plated on spectinomycin plates and no colonies appeared. This 
suggests that either the mutation frequency experiments with B31-A simply 
selected for spectinomycin-resistant phenotypes already present in the population, 
or that spectinomycin resistance and kanamycin /gentamicin resistance are not 
compatible in B. burgdorferi. The concentration of spectinomycin that B31-A was 
exposed to and the number of cells in the culture media did not affect the
7  ofrequency of mutants. Plating 10 or 10 cells at concentrations of 1.5,6.0, and 30 
pg/ml of spectinomycin resulted in similar numbers of colonies appearing on 
plates (Table 3). This indicates that neither of these factors affects the 
spectinomycin-resistance phenotype. Similar observations were made with B. 
burgdorferi N40 resistant to erythromycin suggesting that the frequency of 
resistant cells was probably due to the maintenance of a small population of 
erythromycin-resistant N40 B. burgdorferi in the population (14).
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The frequency of spectinomycin-resistant mutants is considerably higher 
than the frequencies of the aminoglycoside-resistant mutants also reported in this
o
study. The frequency of kanamycin-resistant mutants is approximately 1.3 x 10 ', 
the frequency of streptomycin mutants is 3.4 x 10'9 and gentamicin 1.0 x 10'8.
Although the methods used in our experiments are different from those of 
other researchers who used methods pioneered by Luria and Delbruck (93), 
Newman (94) or Lederberg and Lederberg (95), comparisons o f the mutation rates 
for other organisms that have mutations conferring spectinomycin-resistance are 
informative. The B. burgdorferi spectinomycin-resistant phenotypic frequency 
recorded in this study is considerably higher than the spectinomycin-resistant 
mutation frequency reported for E. coli and Salmonella enteritidis (96). 
Spectinomycin-resistant mutants appear at a frequency of 2 x 10'9 in E. coli and 3
x 10'8 in S. enteritidis (96). The frequency of spectinomycin-resistance in 60
• • 8pg/ml spectinomycin is approximately 10" for Mycoplasma mycoides (97).
o
These mutation rates, along with rifampicin-resistant mutation rates of 1.2 x 10"
o
for E. coli and 2x10" for S. enteritidis, have been identified as typical random 
mutation rates for bacteria (45, 96,98). Increases in mutation rates have been 
identified in organisms that have defective methyl-directed DNA mismatch repair 
systems, which are catalyzed by proteins encoded by the mut, dam and uvrD 
genes (96, 98,99). Mutations in these genes, referred to as mutator genes, can 
increase the incidence of mutation 10-100 times (96). The increased mutation 
frequency in mutator strains matches the mutation frequency for spectinomycin- 
resistance mutants observed in our experiments with B. burgdorferi. Mutator
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genes have not been sequenced to determine if this is the cause of the increase in 
mutation rate in B. burgdorferi. However, if any of these mutants were a mutator 
strain we would predict that there would be an increase in resistance to all of the 
antibiotics tested.
The frequency of spectinomycin resistance in B. burgdorferi is similar to 
the frequency observed for spectinomycin-dependent mutants in E. coli, which is 
10'6 (85). It is lower than the 4 x 10'5 frequency for the secondary mutation in B. 
subtilis that confers resistance for spectinomycin-dependent B. subtilis (84). 
Although the high mutation frequencies hint at spectinomycin dependence in the 
B. burgdorferi mutants, plating the SPR3 and SPR6 mutants on BSK plates with 
no antibiotic produced as many colonies as plating with spectinomycin (Tables 8 
and 10). There also were no secondary mutations found in the rpsE gene encoding 
S5 or additional mutations in the 16S rRNA gene that would be characteristic of 
this phenotype. This suggests that a secondary mutation, conferring 
spectinomycin-dependence, is not present in SPR3 or SPR6 to account for the 
apparently high mutation rates.
The doubling times (growth rates) for SPR3 and SPR6 were both 8.1 
hours during log phase, which is not significantly different from the 7.9 hours for 
B31-A. The aminoglycoside-resistant mutant doubling times, 8.0 hours for SmR4 
and 8.8 hours for KanR/GenR, were also not significantly different than those of 
B31-A, suggesting that there was too much variability in the data to detect the 
differences. Statistically significant changes in doubling times have been found in 
B31 that possess gyrB mutations although the doubling time reported by Samuels
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et al. of 10 hours for B31 was calculated over several days and not just at log 
phase, which accounts for the discrepancy with the current study (73). The 
difference in the doubling times between SPR3 or SPR6 and B31-A was not 
statistically significant, which reflects the results found for other spectinomycin- 
resistant organisms with mutations in 16S rRNA. Spectinomycin-resistant 
ribosomes in E. coli had no effect on growth rates (79) and Cl 192U mutant 
ribosomes were as efficient as the wild-type in E. coli (12). There is little or no 
difference between growth rates of wild-type E. coli and 16S rRNA Cl 192U 
mutants (B. burgdorferi Cl 186U) (87). In this experiment, a plasmid was 
constructed carrying the Cl 192U mutation in a 16S rRNA gene and inserted into 
E. coli. The doubling time, 42 minutes, for this spectinomycin-resistant clone 
containing 80% mutant ribosomes was the same as wild-type E. coli (87). A 
similar experiment was performed with Salmonella enterica where the Cl 192U 
mutant 16S rRNA gene was cloned into a plasmid and tested for resistance and 
doubling time (86). The doubling time of the mutant clone was 38 minutes 
compared to 33 minutes for the wild-type (86).
The small and statistically insignificant differences in doubling time 
among the spectinomycin-resistant mutants may not account for the reduced 
numbers of these mutants compared to B31-A in competition assays spanning 100 
generations. However, SPR3 and SPR6 were better able to compete with B31-A 
than either of the aminoglycoside-resistant mutants, SmR4 and KanR/GenR.
After 100 generations of competition between B31-A and SPR3 or SPR6,18% 
and 8%, respectively, of the cells were the mutant spectinomycin-resistant type.
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The increase in B31-A cells in the cultures of B31-A+SPR3 and B31-A+SPR6 is 
evident from the plating data at the beginning of the assay, which show more 
mutants present (Table 8), the plating data at 50 generations, which show 41% of 
the cells to be SPR3 or SPR6 (Table 9), and the plating data at 100 generations 
showing a further decrease in mutant cells (Table 9). In a competition assay with 
wild-type E. coli and three strains that had mutations in the 16S rRNA binding 
site with S8, wild-type ribosomes were able to out-compete mutants when grown 
in M9 medium with glucose as the only carbon source for metabolism (79). The 
doubling time of the variants was reported to be the same as wild-type, but after 
30 doublings in M9 medium, 100% of the cells in the culture were wild-type E. 
coli (79). However, culturing the wild-type and mutants in Luria broth (LB) 
resulted in one of the variants being as numerous as the wild-type after 30 
doublings (79). These experiments suggest that frequency of a mutant in a 
population depends on the environment and the resources that are available for the 
mutant. Based on these results, and the results of the competition assays with 
spectinomycin- and aminoglycoside-resistant mutants in B. burgdorferi, 
mutations in 16S rRNA may affect the ability o f the mutants to utilize the 
resources in the culture medium as efficiently as the wild-type, resulting in 
reduced ability to compete with wild-type. The high frequency of the 
spectinomycin-resistant mutants (6 x 10"6) compared to the aminoglycoside- 
resistant mutants in the B31-A population is likely the result of the lower fitness 
cost and the increased ability to compete.
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Cloning the SPR3 16S rRNA gene into the pBSV2RII plasmid and 
transforming it into B. burgdorferi strain B31-F did not produce spectinomycin- 
resistance. Sequencing cellular 16S rRNA from strain B3 l-F/pVSPR3 suggests 
there is only wild-type 16S rRNA in the cell and the mutant 16S rRNA is not 
being transcribed from the plasmid. This explains why the plasmid did not confer 
any spectinomycin resistance. There could be several reasons for the gene not 
being expressed. The gene may be missing part of the promoter element, it may 
not be transcribed efficiently on the plasmid, the plasmid may be unstable, or the 
wild-type 16S rRNA gene may have recombined with the plasmid.
E. coli merodiploids carrying spectinomycin-resistant and sensitive genes 
have been made and characterized by other researchers (100, 101). There was no 
apparent increase in resistance of heterozygous individuals carrying both resistant 
and sensitive ribosomes. Unfortunately, the source of mutation conferring the 
resistance was not reported (100,101). E. coli heterozygous merodiploids 
carrying streptomycin-resistant rrn genes have also been shown to be recessive 
(100, 101,102). A plasmid carrying a 16S rRNA gene with the Cl 192U mutation 
confers high levels spectinomycin resistance in E. coli and Salmonella as 
previously mentioned (86, 87). Merodiploids with plasmid Cl 192U 16S rRNA in 
E. coli and Salmonella did confer spectinomycin resistance indicating the mutant 
16S rRNA provides at least a cumulative effect if  not a dominant one (86). In 
addition to these experiments, Salmonella 16S rRNA with the Cl 192U mutation 
was transformed into two strains of E. coli (86). In the first experiment, E. coli 
that had all seven rrn (16S rRNA) genes knocked-out was transformed with a
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plasmid carrying the Salmonella spectinomycin-resistant 16S rRNA gene. The 
resulting transformants were spectinomycin-resistant. However, using an E. coli 
strain with its own wild-type rrn genes and the plasmid carrying the Salmonella 
spectinomycin-resistant C1192U 16S rRNA did not provide resistance to 
spectinomycin. Although Salmonella and E. coli 16S rRNA are 97% identical in 
sequence (103), E. coli 16S rRNA was hypothesized to out-compete the 
Salmonella mutant 16S rRNA for ribosomal proteins, transcription factors and 
ribosomal assembly (86). The B. burgdorferi spectinomycin-resistant plasmid- 
borne 16S rRNA gene is identical in sequence (with the exception of the Cl 186U 
mutation) to the wild-type, making competition for ribosomal proteins and 
ribosomal assembly unlikely. The copy number of the plasmid in the cell may 
factor into the amount of Cl 186U 16S rRNA present and it may also be out- 
competed for transcription factors by chromosomal rrn genes. The pBSV2 
plasmid, from which the pBSV2RII was derived, appears to have a higher copy 
number than chromosomal 16S rRNA, but the copy number for pBSV2RII is 
unknown (76, 77). Furthermore, the conflicting results from E. coli studies 
determining spectinomycin resistance of the heterozygous merodiploid may be a 
function of the different plasmids that were used as vectors in the individual 
experiments.
There are additional factors that should be considered as well. The 
difficulty in transforming B31-A with pVSPR3 may indicate that the plasmid is 
not very stable. Although several plasmids with antibiotic-resistant markers have 
been successfully transformed in B. burgdorferi (77), including pBSV2, there
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have been a few problems cloning and transforming plasmids in B. burgdorferi 
(78). For example, the B. burgdorferi plasmid cp9 from strain N40 was 
successfully cloned into pCR-XL-TOPO and reported to be quite stable. 
However, when cp9 was cloned into pBluescript, the resulting plasmid was 
unstable in spite of having the same origin of replication, and similar size and 
copy number as pCR-XL-TOPO (78).
5.2 Kanamycin and Gentamicin Resistance
The aminoglycosides, kanamycin and gentamicin, form several hydrogen 
bonds along the major groove of helix 44 in 16S rRNA (39,41) causing 
miscoding of mRNA during translation of the nascent polypeptide (36, 39). 
Resistance to these antibiotics in E. coli is conferred as a result of U1406A or 
A1408G mutations in 16S rRNA that reduce the binding affinity of the antibiotic 
for helix 44 (36,42).
We have identified an A1402G mutation in B. burgdorferi strain B31-A 
conferring a high level of resistance to kanamycin and gentamicin (Figure 12). 
This mutation appears at a frequency of 1.3 x 10'8 on kanamycin plates and 1.0 x 
10'8 on gentamicin plates, which is in the range of frequencies considered typical 
for random mutations in bacteria (47,95, 97). With an I C 5 0  > 800 pg/ml for 
kanamycin and > 600 pg/ml for gentamicin, this mutation is about 100-fold or 
more resistant to both antibiotics (Table 4). This high level of resistance to 
kanamycin and gentamicin is also found in E. coli with the homologous A1408G
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mutation (36,42) and Mycobacterium tuberculosis with the homologous A1400G 
mutation (44).
Susceptibility to the antibiotics spectinomycin and streptomycin increases 
with the A1402G mutation. The IC50 of spectinomycin and streptomycin for the 
KanR/GenR mutant is about half the IC50 for wild-type B31 -A (Table 4). The 
increased susceptibility of the KanR/GenR mutant to streptomycin eliminates the 
possibility that this mutant carries an additional mutation that would produce a 
streptomycin-dependent phenotype (59). One possibility for the observed 
changes in susceptibility to these antibiotics caused by the A1402G mutation has 
already been discussed regarding spectinomycin resistance. A change in 
susceptibility to other antibiotics is likely due to structural changes along the 16S 
rRNA that alter helix-helix interactions or increase the affinity that antibiotics 
have for their binding sites. Helix 44, the site of kanamycin and gentamicin 
binding, interacts directly with helices 27 and 34 (11,91). These two helices 
harbor binding sites for streptomycin (H27 and H44) and spectinomycin (H34) 
(11,91). Additional interactions that may be affected involve the S5 protein that 
interacts with all three helices and the S12 protein that interacts with helices 27 
and 44 (91, 92).
Although not statistically significant, the KanR/GenR growth rate of 8.8 
hours is slower than B31-A (7.9 hours) and the other antibiotic-resistant mutants 
SPR3, SPR6 and SmR4 (Table 7). The growth rate for the homologous E. coli 
A1408G mutant is identical to the wild-type even with the addition of 160 pg/ml 
kanamycin (36). The E. coli A1408G mutant also does not affect ribosomal
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activity suggesting this mutant may be able to compete with wild-type E. coli (36, 
42). B. burgdorferi carrying the A1402G mutation may have deleterious effects 
on ribosomal function responsible for the slower growth rates. In addition to 
slower growth rates, the KanR/GenR mutants were unable to compete with wild- 
type B31-A in competition assays. After 50 generations, less than 1% of the cells 
in the B31-A+KanR/GenR culture tubes were KanR/GenR. At 100 generations, 
no KanR/GenR cells were detected indicating that all of the remaining cells were 
B31-A. The slower growth rate alone may account for the inability of 
KanR/GenR mutants to compete with B31 -A. However, the B31 -A+SmR4 
competition assay produced the same results despite SmR4 having a growth rate 
virtually identical to B31-A, indicating there may be other metabolic factors 
involved in the competition with wild-type. The frequency of the KanR/GenR 
mutant in the B31-A population may reflect how well this mutant is maintained as 
well as how often the mutation arises. This scenario matches the data for mutation 
frequencies and competition assays, which show SPR3 and SPR6 are more able 
to compete with wild-type and, therefore, more frequent than SMR4, which is 
unable to compete with wild-type and less frequent than the spectinomycin- 
resistant mutants. It also reconciles the results of the statistical analysis that 
indicate the differences in growth rates are not significant although the less 
frequent mutants KanR/GenR and SmR4 do not compete as well as the 
spectinomycin-resistant mutants with B31-A.
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5.3 Streptomycin Resistance
Streptomycin disrupts translational accuracy by increasing the affinity for 
noncognate aminoacyl tRNA molecules at the A-site and interfering with the 
ability to accurately proofread during translation (45,46). This error-prone 
activity is induced when streptomycin binds at several sites along the 16S rRNA 
phosphate backbone and to the ribosomal S12 protein (11,47,48, 49, 50). 
Mutations at several sites in the 16S rRNA gene and the rpsL gene encoding the 
S12 protein have been identified as conferring resistance to streptomycin in many 
organisms (47,48, 51, 52, 53, 54, 55).
We have identified two mutations in the B. burgdorferi rpsL gene 
conferring resistance to streptomycin. These mutations encode K88R and K88E 
amino acid substitutions in the ribosomal S12 protein. The frequency of the
O  Q
streptomycin-resistant mutations, which is between 2x10" and 3.4 x 10' for B. 
burgdorferi, is in agreement with published reports (47, 96,98) for bacterial 
mutation rates and similar to those for B. burgdorferi KanR/GenR. This frequency 
includes both the K88R (SmR3) and K88E (SmR4) mutations and falls within the 
range given for other streptomycin-resistant bacteria. The mutation frequency for 
the rpsL gene in M. smegmatis is 10'8 to 10'10 (47), and 2 x 10'10 for E. coli (65). 
rpsL mutation frequencies in T. thermophilus are considerably higher at 10'7 (62). 
The frequency of K88R and K88E mutants is similar to that of the kanamycin- 
resistant mutation and 100-fold less frequent than the spectinomycin-resistant 
mutants.
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Neither mutant exhibited any of the characteristics associated with 
streptomycin dependence. Complete sequencing of the rpsL and 16S rRNA genes 
revealed no secondary mutations associated with streptomycin dependence. 
Another characteristic of this phenotype is an increased resistance to kanamycin 
and gentamicin. Although the level of resistance to kanamycin did increase two­
fold, the SmR4 mutant was able to grow in BSK plates without streptomycin. The 
ability to grow without streptomycin in the medium is not characteristic of the 
streptomycin-dependent phenotype. Plates with 35 pg/ml streptomycin and plates 
without streptomycin grew nearly identical numbers of SmR4 colonies indicating 
that SmR4 was not dependent on streptomycin for growth in a solid medium.
The level of streptomycin-resistance was approximately 7-fold for SmR3 
and 10-fold for SmR4 compared to the wild-type (Table 4). These resistance 
levels are much lower than those for SPR3, SPR6 and KanR/GenR, which are all 
>100-fold more resistant than wild-type to their respective antibiotics. Apparently 
in B. burgdorferi, mutations in 16S rRNA gene encoding the region of 
spectinomycin and kanamycin binding are able to confer much higher levels of 
resistance compared to mutations located in the genes for 3OS proteins (SI2) that 
interact with streptomycin. The levels of resistance in B. burgdorferi are typical of 
other streptomycin-resistant mutants. Similar susceptibilities have been identified 
in M. smegmatis that have the homologous mutation in rpsL encoding the S12 
protein as well as in 16S rRNA (47). The S12 K88R, K88E and the 16S rRNA 
530 stem loop substitutions identified in M  smegmatis were all 5 to 10-fold more
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resistant to streptomycin than the wild-type (47). Anis. coli C912U substitution 
conferred four-fold resistance (50).
The slight differences in streptomycin-resistance between SmR3 and 
SmR4 are likely caused by a change in the electrochemical charge at residue 88 in 
the S12 protein, although this difference was not observed in either M. smegmatis 
or T. thermophilus (47, 62). The arginine substitution in SmR3 retains the positive 
charge of the wild-type lysine residue. In spite of the charge remaining the same, 
conformational changes in the S12 protein must occur upon substituting arginine 
and its two additional side chain amino groups. The glutamic acid substitution 
creates a residue at position 88 with a negatively charged side chain altering the 
S12 structure from the wild-type. These changes perturb the structure of S12 and 
alter the global structure of the ribosome reducing the stability of the region 
around helix 27 in T. thermophilus (11, 104). The decrease in stability from the 
K88R and K88E mutations may compensate for the increased stability created by 
streptomycin binding and allow the ribosome to switch between the error prone 
ram state and the hyper accurate restrictive state, restoring nearly normal 
ribosome function while providing streptomycin resistance (11).
Susceptibility assays revealed changes in susceptibility to spectinomycin, 
gentamicin, and kanamycin in both K88E and K88R strains. The two mutants 
were half as resistant to spectinomycin and gentamicin and two-fold resistant to 
kanamycin (Table 4). As discussed previously, these changes in susceptibility 
must be due to global changes along the 16S rRNA. Several lysine and arginine 
residues of T. thermophilus S12 including the homologous K88 contact helix 27
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with additional residues contacting helices 18 and 44 (11,90,104). The K88R 
and K88E mutations could disrupt the S12 interactions with any of these three 
helices and alter the binding affinity of spectinomycin, kanamycin or gentamicin. 
S12 has been proposed to facilitate the helix 27 accuracy switch (48) that enables 
the ribosome to change from the error prone ram state to the hyper accurate 
proofreading state (11,48). Mutations causing modifications to the SI 2-helix 27 
interaction may disrupt other helix-helix interactions as well. The helix 27 switch 
may activate a series of switches along the 16S rRNA including helix 34, which is 
the site of spectinomycin binding, and helix 44, which is the site of kanamycin 
and gentamicin binding (11). S12 also has direct contact with the upper portion of 
helix 44 (91,104). The K88E and K88R substitutions may cause conformational 
changes along helix 44 that alter binding affinities for kanamycin and gentamicin, 
thus changing the susceptibilities to these antibiotics.
The doubling time during log phase was 8.0 hours for SmR4, which is 
roughly the same as wild-type B31-A (7.9 hours). In competition assays, SmR4 
was unable to compete with B31-A indicating a significant fitness cost for this 
mutation. SmR4 comprised only 6% of the cell population at 50 generations and 
was undetectable at 100 generations. This follows the pattern of the slower 
growing KanR/GenR mutant that also had no detectable cells after 100 
generations in co-culture with B31-A. The homologous A1408G 16S rRNA and 
S12 mutations have been shown to affect the selection of cognate tRNAs and the 
rates of polypeptide chain elongation in E. coli and T. thermophilus (36,105,
106). Mutations in the E. coli rpsL gene slow the rates of polypeptide chain
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elongation by nearly 20% (105). A slower rate of translation could explain the 
inability of SmR4 and KanR/GenR to compete with wild-type B31-A, but should 
also be accompanied by slower growth rates that are found only in the 
KanR/GenR mutants. It may also help to explain why the SPR3 and SPR6 
mutants are able to compete much better in competition with B31-A. 
Spectinomycin-resistant mutations have been shown to have little if  any affect on 
ribosome function even in the absence of antibiotic (24,25). Normal ribosome 
function in SPR3 and SPR6 certainly could provide a fitness advantage that 
accounts for the differences in ability to compete with B31-A among the four 
mutants SPR3, SPR6, SmR4 and KanR/GenR. The decreased fitness, based on 
ribosome function, for the SmR4 and KanR/GenR mutants likely explain why 
they are less common in a population of B31-A than SPR3 and SPR6.
Slower translation rates should result in significantly slower growth rates. 
Since SmR4 grows at the same rate as wild-type B31-A, the inability of SmR4 to 
compete may be from deleterious effects on another S12 cellular role. If S12 is a 
bifunctional protein this would provide an alternative explanation for the near­
normal growth, coupled with the inability of SmR4 to compete with B31-A for 
resources in the medium. Another ribosomal protein, S3, is bifunctional in 
Drosophila with roles in both translation and DNA repair (107), and several other 
ribosomal proteins have been shown to be bifunctional as well (108,109).
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5.4 Coumermycin Ai Resistance
Coumermycin Ai is a competitive inhibitor o f the enzymatic action of 
GyrB (69). Coumermycin Ai binds to GyrB at residue T165 in E. coli 
(homologous to T 162 in B. burgdorferi) preventing ATP hydrolysis necessary for 
the catalytic activity of DNA gyrase (68). This reaction relieves torsional stress 
caused by supercoiling resulting from transcription and replication (68). 
Mutations in gyrB encoding substitutions at T165 and other residues have been 
identified conferring resistance to coumermycin A] and other coumarin drugs 
such as novobiocin (69, 70, 71).
We have identified one natural coumermycin Ai-resistant mutation and 
four mutants generated by site-directed mutagenesis. The naturally occurring 
mutant has a T162I amino acid substitution and the four site-directed mutants are 
T162F, T162L, T162M and T162S. Resistance levels vary considerably for each 
of the mutations and are probably a result of disrupting the water-mediated 
hydrogen bond between the side chain hydroxyl group of threonine 162 and 
coumermycin Ai (69). The T162I mutant is 420-fold more resistant than wild 
type. This level of resistance is considerably more than reported for a Bartonella 
bacilliformis T162I mutant, which was only 5-fold more resistant (71). However, 
it is similar to the B. burgdorferi R133I GyrB mutation that is 300-fold more 
resistant (73). As noted previously with spectinomycin resistance in E. gracilis 
and Anacystis, species-specific interactions with the antibiotic could be 
responsible for the observed difference in resistance (88). The least resistant of 
the mutants is T162S, which is 5-fold resistant to coumermycin Aj. The side
104
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
chain of serine is structurally similar to that of threonine. This similarity probably 
allows some hydrogen bonding, or does not change the conformation of GyrB 
sufficiently to interrupt the other coumermycin Ai contacts at residues G74 and 
R133. In E. coli, the homologous T165S mutant does not confer resistance to 
novobiocin, a structurally similar, but less potent inhibitor o f gyrase activity (67, 
72,110). This may explain why mutations in E. coli R136 are the main sources of 
resistance to coumermycin Ai (72). Alternatively, the reported difference in 
resistance between E. coli and B. burgdorferi at this residue may be the result of 
species differences in the interaction of GyrB and coumermycin Ai, or 
biochemical differences between novobiocin and coumermycin Ai, which is 
essentially a dimer of novobiocin.
The T162L mutant that is 4000-fold more resistant to coumermycin Ai 
than the wild-type or about ten-fold more resistant than the T162I mutant is 
particularly puzzling. These two amino acids have side chain isomers that would 
seem to provide a similar chemical milieu for coumermycin Ai. To further 
confuse this situation, R133I and R133L mutants have these levels of resistance 
reversed with R133I conferring 10-fold more resistance than R133L (B. Eggers 
and D.S. Samuels, unpublished data). The T162M mutation is 80-fold resistant 
and nearly matches the 100-fold resistance of an R133M mutation (B. Eggers and
D. S. Samuels, unpublished data). The most resistant of the T162 mutants is 
T162F. This is likely due to the bulky aromatic ring of the phenylalanine side 
chain, and along with the nonpolar leucine (T162L) and isoleucine (T162I), lacks 
the ability to form hydrogen bonds. T162F conferred resistance up to 6000-fold
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more than B31-A. A nonpolar side chain mutant T166A (.B. burgdorferi T162) in 
the spirochete Brachyspira hyodysenteriae conferred coumermycin Ai resistance 
400- to 500-fold over the wild-type (111), which is within the range of resistance 
levels found in this study. Other nonpolar side chain mutants, the homologous E. 
coli T165A and T165V, have been reported to increase the novobiocin IC50 for 
ATPase to 18 and 13-fold (110). The T173N (B. burgdorferi T162) mutation in 
Staphylococcus aureus conferred 120-fold resistance to coumermycin Ai, but 
produced just two-fold resistance to novobiocin indicating that nonpolar 
mutations may provide more resistance to coumermycin Ai than novobiocin (70). 
These levels are considerably less than the resistance in B. burgdorferi.
The doubling time of T162F is significantly slower than B31-A, and is 
probably a result of the substitution from the polar side chain of threonine to the 
nonpolar aromatic ring of phenylalanine. The conformational changes in gyrase 
resulting from this substitution would provide a logical explanation for a decrease 
in gyrase function that is manifested in the slower growth rate. Substituting 
residues in gyrase from charged or polar residues to nonpolar alanine residues in
E. coli has been shown to decrease activity (110). This could explain the 
decreases in growth rates for the T162 mutants that have nonpolar side chains. 
The slowest growing mutants, T162L (8.7 hours), T162I (8.6 hours), T162M (8.6 
hours) and T162F (13.9 hours), all have nonpolar side chains that may reduce the 
ATPase activity of GyrB. This in turn could interfere with replication and 
transcription associated with growth. The doubling time of B. burgdorferi 
coumermycin Ai resistant R133I mutants was about 10% slower than the wild-
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type (73), which is similar to the growth rate of the T162I mutant. The growth 
rate of T162S is slightly slower than the wild-type at 8.2 hours but faster than the 
nonpolar substitutions, which may be a reflection of near normal gyrase activity 
resulting from the retention of a polar amino acid at residue 162.
5.6 Conclusion
Several mutations in the 16S rRNA gene and rpsL encoding 30S 
ribosomal protein S12 have been identified conferring resistance to 
spectinomycin, streptomycin, kanamycin or gentamicin in B. burgdorferi, 
including an AI 191G (B. burgdorferi AI 185G) mutation that has not been 
previously reported in bacteria. Random site-directed mutagenesis generated 
additional B. burgdorferi mutants resistant to coumermycin Ai in addition to a 
naturally occurring mutant.
The frequency of spectinomycin-resistant mutants was approximately 6 x 
10"6. Growth and competition assays suggest this frequency results from the 
ability of these mutants to compete with wild-type B31 -A for resources. Typical 
bacterial mutation rates are 100-fold lower than those for the SPR3 and SPR6 
spectinomycin-resistant mutants. Mutation rates for the three aminoglycoside- 
resistant mutants are similar to those typically reported for bacteria. Neither of 
these mutants, SmR4 or KanR/GenR, competed with wild-type B31-A indicating 
a higher fitness cost than the SPR3 and SPR6 mutants to maintain these mutations 
in the population. Although the growth rate for SmR4 was essentially the same as 
the wild type, this mutant was unable to compete with B31-A. The slower growth
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rate o f the KanR/GenR mutants is not statistically significant although it could be 
a reason for the inability of this mutant to compete with B31-A. Reduced 
ribosomal function, which has not been observed in homologous E. coli mutants, 
may also account for the inability of this mutant to compete with wild-type B31-
A. The higher fitness cost measured by the inability of the KanR/GenR mutants 
to compete with wild-type B31-A is likely the reason for the lower frequencies of 
these mutants in the population compared to the spectinomycin-resistant mutants.
Levels of antibiotic resistance were very high for SPR3 (1500-fold), SPR6 
(>2500-fold) and KanR/GenR (>100-fold) all of which had mutations in the 16S 
rRNA gene. Streptomycin resistance conferred by the two S12 mutations K88R 
and K88E were considerably lower at 7- and 10-fold, respectively, but were 
similar to those reported for other streptomycin-resistant microorganisms. Cross­
resistance in SPR3, SPR6, SmR3, SmR4 and KanR/GenR suggest each of the 
mutations cause conformational changes along the 16S rRNA that affect 
interactions not associated with the respective antibiotics.
None of the mutants exhibited an antibiotic-dependent phenotype. All had 
comparable plating efficiencies and growth rates with or without antibiotic 
selection.
Levels of coumermycin Ai resistance and growth rates appear to be 
directly related to the side chain substitutions at residue 162 of GyrB. 
Substitutions of the polar side chain of threonine to nonpolar side chains (T162F, 
T162L, T162I) increase resistance to coumermycin Ai over 420-fold with the 
most dramatic increase from the aromatic side chain of phenylalanine (6000-fold).
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Consistent with this observation is the substitution of serine with a polar side 
chain conferring only a five-fold increase in resistance. Growth rates also 
followed this pattern, with T162F being the slowest growing mutant and T162S 
growing faster than the nonpolar substitutions. T162M, although possessing a 
nonpolar side chain, had a growth rate equal to the wild-type B31-A. This may be 
due to the unique side chain with sulfur providing resistance to coumermycin Aj, 
but not inhibiting normal gyrase function.
5.7 Future Research
The experiment to determine if  the spectinomycin-resistant 16S rRNA was 
dominant or recessive was inconclusive. A new vector, such as pBSV2, might be 
used to provide adequate expression of the mutant gene. Ribosomal activity using 
a CAT reporter/assay could be done to determine mutant ribosome activity versus 
the wild-type. Reduced ribosomal activity may be responsible for the slower 
growth rates and one of the fitness costs of the mutation. Footprinting of the 
mutant 16S rRNA with each of the antibiotics may confirm whether antibiotic 
affinity is affected by the mutations. Spectinomycin binding affinity should be 
assessed in the AI 185G 16S rRNA mutant. A more accurate evaluation of the 
competition assays could be achieved by performing an RNA primer extension 
from the competition cultures to measure the relative amounts of mutant 16S 
rRNA versus wild-type. Additional searches should be made with infectious 
strains of B. burgdorferi to see if the mutants are associated only with non- 
infectious strains or if they are present in all populations of B. burgdorferi. A
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dominant antibiotic-resistant mutation in an infectious strain may prove to be 
clinically relevant.
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